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Abstract 
Human immunodeficiency virus-1 (HIV-1) is a worldwide epidemic, which cannot be 
eliminated by any current therapeutics, even with highly active antiretroviral therapy, 
which only can control virus replication. A safe and effective vaccine against HIV-1 that 
can elicit both potent humoral and cellular responses has been considered a best solution 
to prevent the infection or to reduce the viral load. However, despite the fact that over 
250 clinical trials have been conducted based on different concepts, no vaccine has been 
successfully developed. The extraordinary diversity of HIV-1, the capability of the virus 
to escape from the adaptive immunity, the difficulty in inducing broadly neutralizing 
antibodies, and the lack of clear immune correlates of protection represent the major 
challenges obstructing the development of HIV-1 vaccines. Designing a peptide-based 
vaccine that stimulates cytotoxic T lymphocytes (CTLs) specifically against the highly 
conserved epitopes in HIV-1 has been considered a promising strategy.  This can provide 
two theoretical advantages: maximizing the immunological coverage and minimizing the 
viral escape from recognition of T cells. However, owning to the short sequence 
(normally 8-10 amino acids for CTL epitopes), these conserved epitopes are weakly 
immunogenic, requiring potent adjuvants to boost the efficiency. Some novel strategies 
have been reported to achieve an efficient adjuvant without causing any side effect. 
Among them, nanoparticle based delivery systems that can provide targeted delivery to 
immune cells and/or self-adjuvant effect, are emerging as a promising approach.  
In this thesis, we present a self-assembling peptide based delivery platform efficiently 
integrating antigenic peptides and immune potentiators in the formulation of a 
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nanoparticle vaccine, and evaluate the immunogenicity in vitro and in vivo. Three parts 
are involved in this work: (1) feasibility study of the delivery of HIV-1 CTL epitope with 
the self-assembling peptide EAK16-II (sequence: AEAEAKAKAEAEAKAK) and the 
cross-presentation efficiency by dendritic cells (DCs); (2) co-delivery of an antigenic 
peptide and a toll like receptor (TLR) agonist within one nanoparticle to target and 
maturate DCs, leading to enhanced CTL response; (3) formulating a prophylactic peptide 
vaccine against HIV-1 by the combination of CD4 epitope-conjugated EAK16-II, CD8 
epitope-conjugated EAK16-II, and a TLR agonist R848, which was subsequently 
assessed the immunogenicity in the transgenic mice.  
The peptide EAK16-II could self-assemble into nanofibers, which were stable in the 
acidic environment and in the presence of proteases. We hypothesized that by directly 
conjugating HIV-1 CD8 epitope with EAK16-II, the fibrillar structures of the conjugate 
would enhance the stability of epitope and thus improve the immunogenicity. To verify 
this, the CD8 epitope SL9 was conjugated with EAK16-II to obtain the epitope-loading 
peptide SL9-EAK16-II. Physicochemical characterizations revealed SL9-EAK16-II 
spontaneously assembled to short nanofibers in PBS, which were more stable in serum or 
oligopeptidase than unstructured SL9. Ex-vivo generated DCs that were pulsed with SL9-
EAK16-II and activated by maturation cytokines, stimulated more poly-functional CD8+ 
T cells. This augment was explained by the evidence that SL9-EAK16-II was degraded 
more slowly than SL9 within DCs, therefore prolonging the stimulation to CD8 T cells.  
Moreover, the results from confocal microscopy suggested the cytosolic pathway for the 
cross-presentation of SL9-EAK16-II.   
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However, SL9-EAK16-II itself failed to maturate DCs after internalization, which might 
cause antigen tolerance. To avoid the induction of tolerance and further enhance the 
antigenicity of epitope SL9, TLR agonist R837 or R848 was incorporated into the 
nanofiber formulation. The data from fluorescence spectra and calorimetric titration 
suggested the co-assembly between SL9-loaded nanofibers and TLR agonist was mainly 
driven by hydrogen bonding and hydrophobic interactions. The SL9-EAK16-II/R848 co-
assemblies strongly facilitated the activation of DCs, and stimulated significantly more 
epitope specific CTLs when assessed in the form of DC based vaccine.  
The in vitro studies implied the potential of the self-assembling peptide EAK16-II as a 
nanocarrier in the formulation of vaccine. We further determined the applicability of this 
formulation in vivo. Since the activation of CD4+T cells plays a critical role in the 
generation of functional memory CTLs, we incorporated an additional CD4 epitope TL13 
into the vaccine formulation, via conjugating with EAK16-II. The new formulation of 
antigen was characterized as nanofibers with average size of approximately 220 nm. The 
transgenic mice that were subcutaneously injected with these nanofibers produced as 
much as 1 fold increase in frequencies of SL9 specific CTLs, when compared with the 
mice vaccinated with either the mixture of epitopes and R848, or R848 alone. Moreover, 
almost 90% of the SL9 specific CTLs primed by the nanofibers were central memory 
CD8+ T cells (CD44+, CD62L+), which was the hallmark of the acquired immune 
response. The in-vivo study suggested not only enhanced magnitude, but also higher 
quality of T cell response was induced by the nanoparticle-based vaccine. Our findings 
demonstrated the self-assembling peptide had considerable promise as a delivery 
platform to integrate the principal components for cellular response-focusing vaccines. 
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Chapter	  1 Introduction	  
1.1 Overview	  
Since first discovered in 1983, human immunodeficiency virus (HIV) has become a 
global pandemic, threatening the lives of human beings. This type of retrovirus can infect 
several human cells, especially some important immune cells, such as CD4+ T helper 
(Th) cells, or dendritic cells (DCs), and consequently destroy the immune system. As 
shown in Fig.1-1, it is believed that the infection process starts from the binding of 
glycoprotein 120 (gp120) on the surface of HIV, with CD4 protein expressed on Th cell, 
which is followed by the fusing of virus and the Th cell membrane, allowing the capsid of 
the virus entering the cells. Inside the Th cell, the capsid releases the genetic material-
RNA and uses reverse transcription to convert RNA to DNA, which is further integrated 
into DNA sequence of the host Th cell. Then HIV can use the host cell’s machinery to 
synthesize viral proteins as the building blocks to assemble into more viruses. These 
newly formed viruses leave the host cell through a “budding” process, and then maturate. 
Targeting the different stages during the virus life cycle, various inhibitors have been 
developed, the combination of which can efficiently suppress the virus replication and 
reduce the viral load to an undetectable level. However, this so-called “highly active 
antiretroviral therapy (HAAT)” strategy cannot eliminate the virus. Moreover, latent 
HIV-1 reservoir established during acute infection in memory CD4+ T cells has a 
remarkably long half-life and is resistant to HAAT, resulting in the viral rebound in HIV-
1 infected patients who even receive HAAT treatment1. A safe and effective vaccine is 
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undoubtedly the best solution to eradicate the virus and end HIV-1 pandemic. Ideally, 
such a vaccine should elicit humoral response to produce neutralizing antibodies for 
preventing infection by HIV-1, as well as potent cellular response in order to eliminate 
the formation of latent viral reservoir2. Since the first phase-I human trial of AIDS 
vaccine started in 1986, more than 250 clinical trials have been carried out, with only 
three vaccine concepts completing clinical efficacy studies, including monomeric HIV-1 
Env gp120 protein3, RV144 (a recombinant canarypox vector prime, gp120 protein boost 
vaccine regimen), and “STEP” trial (a trivalent mixture of rAd5 vectors expressing HIV-
1 clade B protein Gag, Pol, and Nef)4. However, currently no ideal vaccine that can offer 
the clinical benefit for the protective purpose has been achieved. Thus far, the 
development of an HIV-1 vaccine remains elusive.  
	  
Figure 1-1 Schematic illustration of HIV life cycle. The infection against CD4+ T cell includes: 1) Binding 
between gp120 and CD4; 2) Fusing; 3) Reverse transcription; 4) Integration and replication; 5) Assembling 
and budding; 6) Maturation. 
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Learning from the past clinical trials, several key challenges in the design of HIV-1 
vaccine are summarized, including the extensive viral clade and sequence diversity, early 
establishment of latent viral reservoirs, unclear immune correlates of protection (what 
sort of immune response the vaccine should stimulate), and lack of proper animal model, 
etc.5 The main obstacle is ascribed to the extraordinary HIV-1 protein diversity. Owning 
to the “error-prone” property of HIV reverse transcriptase, the virus populations that 
constantly evolve could be generated within the infected individuals. This extraordinary 
mutability of virus results in the ease of escape from the recognition by the immune 
system. Broadly neutralizing antibodies that are found in ~20% HIV-1 positive long-term 
non-progressors, potentially provide complete protection against infection, however, no 
candidate immunogen can do this so far. The conserved regions to which these antibodies 
are directed, are effectively shielded or only formed after Env protein of virus binding 
with CD4, thus requiring extensive somatic hypermutaion of antibody gene6.  
The failure of an antibody-eliciting vaccine against HIV-1 has promoted a shift in the 
focus of the vaccine development. The vaccine that stimulates HIV-1 specific cytotoxic T 
lymphocytes (CTLs) response has been considered as a possible alternative. CTLs cannot 
eliminate the virus directly, but rather it can control the infected cells by recognizing the 
HIV epitope/ MHC (major histocompatibility complex) class I on the surface of cells via 
their T cell receptor and subsequently destroying the infected cells. Recent studies in 
which a rhesus monkey cytomegalovirus vector with recombinant SIV (simian 
immunodeficiency virus) genes as the immunogen induced potent effector memory CTL 
response and cleared the virus soon after the peak of acute infection7, demonstrated the 
feasibility of this strategy in the control of HIV-1.  
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However, a major difference between SIV and HIV is the higher variability of HIV 
proteins, as highlighted above. For CTL epitopes, a difference of a single amino acid in 
an sequence (~10% variance) results in a 30-50% chance of negating recognition by T 
cells8. To overcome this hurdle, focusing the CTL response on the highly conserved 
epitopes identified in very large patient cohorts is suggested as a promising approach8. 
This strategy offers two theoretical virtues, including maximizing immunologic coverage 
of HIV-1 diversity, and minimizing the viral escape from recognition by CTLs. 
Furthermore, compared with the traditional vaccines utilizing killed, inactivated or 
attenuated microorganisms as the immunogen, antigenic peptide based vaccines provide 
several advantages, particularly with regards to safety and ease of production.  
Nevertheless, owning to the small size of these conserved CTL epitopes (normally 
comprised of 8-10 amino acids), they are poorly immunogenic. Additionally, short 
epitopes can be directly loaded onto MHC molecules, also on non-professional antigen 
presenting cells (APCs), causing the induction of immune tolerance.  Thus, to elicit a 
potent and durable antigen specific cellular response, an efficient adjuvant is normally 
necessary for formulating a peptide-based vaccine. The adjuvant effect can be divided 
into two principle components, including delivery system and immune potentiator9. The 
delivery system can provide the antigenic peptides with the protection against proteolytic 
degradation, and deliver the cargos into the targeted cells, such as DCs. Meanwhile, the 
immune potentiator can activate innate immune cells to provide pro-inflammatory 
environment for the induction of acquired immune response. However, currently only 
few adjuvants are licensed for the use in humans, MF59 (an oil-in-water adjuvant) and 
aluminum salt in Europe, while only aluminum salt in US.  In addition, most adjuvants 
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including alum or Incomplete Freund’s Adjuvant (IFA) have been developed for the 
induction of humoral response, but are weak at eliciting T cell mediated immune 
response. Moreover, many adjuvants use structurally heterogeneous materials, which 
make it challenging to understand their mechanisms10. Thus, the development of a 
simple, yet potent and safe adjuvant is of great importance.  
Nanoparticles, such as liposomes11,12, polymeric nanoparticles13,14, and virus-like 
particles15,16 have been intensively investigated as delivery platforms and/or immune 
potentiators in formulating subunit vaccines. In addition, self-assembling peptides, which 
have been widely developed for application in regenerative medicine17, tissue 
engineering18, also attract considerable attention for vaccine design, owning to their 
biocompatibility, safety, ease of manufacturing, and control over size, shape and surface 
properties. Moreover, when conjugating with an exogenous B cell epitope, self-
assembling peptides are reported to act as self-adjuvant nano-carriers, enhancing the 
antigen specific humoral response10,19. Compared with other biomaterials, self-
assembling peptide based delivery system can provide a number of advantages. First, any 
identified epitope can be easily conjugated with the self-assembling sequence using solid 
phase peptide synthesis. And the conjugation by the peptide bond can also provide higher 
antigen loading efficiency and stability, compared to other loading strategies, such as 
encapsulation, simply mixing, or surface absorption. Moreover, the nanoscale vaccine 
formulations can be directly produced from the self-assembling process, without using 
organic reagents or applying complex preparation procedures.  However, whether self-
assembling peptide could stimulate innate immunity and be applied for enhancing the 
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immunogenicity of T cell epitope, especially HIV-1 protein derived epitope remains 
unclear.  
Thus, in this work we investigated the potential of self-assembling peptide based delivery 
system for the formulation of CTL response-stimulating vaccine towards HIV-1. EAK16-
II, a typical ionic-complementary self-assembled peptide, which is resistant to acidic 
environments and/or the presence of proteases, as well as induced no detectable immune 
response in animal20, was conjugated with an HIV-1 CTL epitope SL9. Physicochemical 
characterizations were carried out to study the self-assembly process of the epitope-
bearing peptide SL9-EAK16-II, including the critical assembling concentration (CAC), 
morphology and hydrodynamic size, as well as the stability of the particles in 
physiological environment. The cross-presentation efficiency of the conjugating peptide 
was then evaluated in the form of DC-based vaccine in-vitro using HIV-1 specific CTL 
recall response as readout. In the next step, the feasibility of the self-assembling peptide 
for co-delivery of epitope and TLR (toll-like receptor) agonist was further assessed. Two 
hydrophobic small organic molecules Resiquimod (R848) and Imiquimod (R837), which 
can activate TLR7/8, were incorporated into the SL9-EAK16-II system to enhance the 
maturation activity towards DCs. Afterwards, an integrated formulation of nanoparticle-
based vaccine consisting of one CD4 epitope, one CD8 epitope, and a TLR agonist 
(R848), was prepared and administrated in transgenic mice to determine the antigen 
specific CTL response by prime-boost strategy. The mice vaccinated with the nano-
formed vaccine generated significantly more antigen specific central memory CTLs. 
According to the results reported in this work, the self-assembling peptide was suggested 
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as an efficient matrix for delivering both antigenic peptide and immune potentiator (TLR 
agonist) to potently induce HIV-1 specific memory CTLs.  
1.2 Research	  objectives	  
	  
The goal of this research is to develop an efficient and safe delivery platform for 
formulating peptide vaccine to elicit potent HIV-1 specific CTL response. To achieve 
this, direct conjugation and non-covalent encapsulation have been applied to incorporate 
the antigen and the immune potentiator within the formulation respectively, to enhance 
the immunogenicity of CTL epitope in vitro and in vivo. The specific objectives of this 
thesis are listed as following: 
1) Synthesis and characterization of epitope-bearing self-assembling peptides to 
protect the degradation of epitope from extra/intra-cellular proteases, as well as 
determining the cross-presentation efficiency by DCs in-vitro. 
2) Incorporation of the TLR agonist within epitope-loaded nanoparticles, and 
evaluation of antigen specific CTL response in the form of DC-based vaccine in 
vitro. 
3) Formulating an efficient nanoparticle based vaccine consisting of CD4+ and 
CD8+ T cell epitopes as well as the TLR7/8 agonist to generate more HIV-1 
specific memory CTLs in vivo. 
1.3 Outline	  of	  the	  thesis	  
The thesis consists of six chapters, of which the scopes are listed in following: 
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Chapter 1 introduces the overview of the thesis, including HIV infection mechanism, the 
development of HIV-1 vaccines with the challenges and new strategies, the importance 
and potential of CTL response in the design of HIV-1 vaccines, and the feasibility of the 
self-assembling peptides-based nanoparticles as delivery platforms in the formulation of 
epitope-based vaccines. Additionally, the objectives and scopes of the thesis are given as 
well.  
Chapter 2 provides a review on peptide based vaccines, in which TLR agonists based 
adjuvants, the existing nanoparticle based delivery system, as well as the cross-
presentation of exogenously administrated peptides by DCs are included. The rational 
design principle for the self-assembling peptides and their biological applications, 
particularly in drug delivery and vaccine design are also reviewed.  
Chapter 3 focuses on the assessment of the cross-presentation efficiency of HIV-1 CTL 
epitope-loaded self-assembling peptide by DCs in vitro. Physicochemical 
characterizations were conducted, and the stabilities of the peptides with the presence of 
serum or oligopeptidase were determined with HPLC. Flow cytometry and confocal 
microscopy were employed to study the persistence and intracellular distributions of the 
peptides within DCs.  
Driven by the fact that the epitope-loaded self-assembling peptide did not show self-
adjuvant capacity, enhancing the immunogenicity, in Chapter 4, the TLR7/8 agonists 
were incorporated into nanoparticles, via non-covalent interactions. The results from 
fluorescence spectra and calorimetric titration demonstrated the co-existence of the 
antigen and the TLR agonist within the nanostructures, which enhanced the DCs 
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maturation, as well as stimulated more antigen-specific poly-functional CD8+ T cells in 
vitro. 
In Chapter 5, to study the immunogenicity of the peptide/agonist co-assemblies in vivo, a 
CD4+ T cell epitope was conjugated with the self-assembling peptide as the same method 
we did for the CD8 + T cell epitope. The morphology of the tripartite nanovaccine was 
characterized as cross-linked nanofibers, of which the immunogenicity was assessed in 
HLA-A2 transgenic mice. From the in vivo results, the mice subcutaneously 
administrated with the nanovaccine produced significantly more HIV-1 specific central 
memory CTLs.  
Chapter 6 presents the conclusions of the studies in the thesis, and the recommendations 
for the future work. 
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Chapter	  2 Literature	  review	  
2.1 Peptide	  vaccine	  
Vaccination has been considered as one of the most successful innovations for public 
health in preventing and eradicating the danger from various diseases, such as smallpox 
and poliomyelitis. The general principle for a traditional prophylactic vaccine is to 
provoke a response from the immune system (humoral and cellular immunity) and create 
a memory within the immune system so that the next exposure to the disease agent will 
be eliminated by primed immune response. In the last two decades, with the knowledge 
about the human immune system better established, the therapeutic vaccine that cures 
chronic infectious patients by inducing or augmenting antibody and/or cellular response 
is also intensively studied. Traditionally, vaccines are developed consisting of dead or 
inactivated pathogenic microorganisms, or purified products derived from the 
microorganisms as the immunogens. These vaccines can induce both humoral and 
cellular immune responses potently, usually requiring only one boost21, however, several 
drawbacks limit the development and application of these vaccines, such as a serious risk 
of reverting back to the virulent form, the possibility of inducing an autoimmune 
response, the intrinsic instability making them hard to administrate, and the complicated 
compositions perplexing the mechanism of the induced immune response22. Moreover, 
many pathogens are difficult to culture in vitro, making the large-scaled manufacturing 
impractical23. Therefore, the new generations of vaccine, which only adopt the specific 
antigenic fractions from pathogens to stimulate appropriate immune response have been 
placed great expectation. So far, protein-, DNA-, or peptide-based subunit vaccines have 
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been intensively examined either in pre-clinical or clinical stages. Benefiting from the 
removal of the unnecessary components, these subunit vaccines offer higher stability and 
safety. Among them, the most precise selection of antigen can be achieved from peptide-
based vaccine, which is the subject of this project.   
Peptide-based vaccines usually incorporate a pool of short or long peptides, which are 
termed as epitopes (antigenic determinant parts of antigens that can be recognized by 
immune system, especially antibodies, B cells or T cells), to induce an adaptive immune 
response, but avoiding allergenic and / or reactogenic response. With the rapid 
development of solid phase peptide synthesis, peptide-based vaccines can be easily and 
economically produced in large scale, with high purity and guaranteed quantity. 
Additionally, peptide vaccines can be designed to induce a broad-spectrum immune 
response against multiple serological variants or strains of a pathogen by formulating 
various non-continued epitopes, or epitopes highly conserved in different strains24. For 
example, a major hurdle in the development of HIV-1 vaccines is the high variability of 
HIV-1, which might be overcome by focusing CD8+ T cell response on multiple 
conserved epitopes derived from HIV-1 proteins8. However, because of the relatively 
small size, the epitopes are easily degraded in body fluid, leading to weak 
immunogenicity when they are administrated alone, and therefore require adjuvants.  
Broadly, adjuvants could be defined as either immune potentiators that can activate innate 
immune cells or delivery systems that are able to stabilize antigens and increase their 
cellular uptake, trafficking and presentation. To date, many adjuvant strategies have been 
developed for peptide-based immunotherapies, such as particulate25,26, oil emulsions27, 
toll-like receptor (TLR) agonists28, immunostimulating complexes (ISCOMS)29, and 
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other biologically degradable materials13. However, currently very few vaccine adjuvants 
are licensed for use in humans, MF 59 and aluminum salts in Europe, while only 
aluminum salts in US. In addition, most adjuvants, including alum, are optimized for the 
effective induction of high antibody serum titers (humoral response), but weak at eliciting 
a cellular, T cell mediated immune response, which is essential for eliminating 
intracellular pathogen associated diseases, such as HIV-1, malaria, cancer, etc. Therefore, 
the development of more efficient and safer adjuvants and delivery systems eliciting both 
humoral and cellular responses is of primary importance.  
2.1.1 TLR	  (Toll-­‐like	  receptor)	  agonists	  as	  adjuvant	  
An adjuvant is broadly defined as anything that can increase the immunogenicity of 
antigens, which functions though a number of ways, including providing an antigen depot 
for increased uptake by DCs, or shielding peptide from degradation. The TLR agonist is a 
kind of emerging adjuvant that offers higher safety and efficiency. TLRs are a family of 
pattern recognition receptors (PRRs) that play a critical role in activating both innate and 
adaptive immune response. They are mainly expressed on innate immune cells, such as B 
cells, macrophages, or dendritic cells (DCs). To date, in humans there have been 10 TLRs 
identified, which locate in different compartments of cells: TLR1, 2, 4, 5, 6 are mainly 
expressed on the cell surface, while TLR3, 7, 8, 9 are located in the endosomal 
compartments with their ligand-binding domains facing the lumen of the vesicle30. From 
the structure, they are type I membrane proteins, consisting of a leucine-rich ectodomain, 
and a cytoplasmic domain, termed as Toll/interleukin-1 receptor (TIR) domain. Each 
TLR can recognize particular structures, usually referred to as “PAMPs” (pathogen 
associated molecular patterns) in bacteria, virus, fungi and other pathogens. Natural 
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ligands binding to TLRs 1-9 have been identified, but not to TLR10. For example, TLR2 
forms heterodimers with TLR1 or TLR6 to recognize multiple lipopeptides, TLR 4 
recognizes lipopolysaccharide (LPS), and TLR7/8 form homodimers to bind with single 
stranded RNA31. In addition to natural ligands, synthetic agonists have been developed 
for some of the TLRs, such as imidazoquinoline derivatives for TLR7, 8 or 7/8.  
The binding of TLRs with natural or synthetic ligands initiates complicated intracellular 
pathways, and results in the secretion of cytokines from immune cells, as well as 
increased phagocytosis by macrophages. Furthermore, TLR activation plays a key role in 
bridging innate and adaptive immunity through their presence in professional antigen 
presenting cells, DCs particularly. Via up-regulating the expression of major 
histocompatibility complex (MHC) or co-stimulatory proteins (CD80 and CD86) on DCs, 
it enhances the antigen presentation to T lymphocytes, eliciting potent immune response. 
However, persistent signaling can be of risk and all TLRs are involved in the 
pathogenesis of acute and chronic inflammation, autoimmunity, cancer, and other diverse 
disease32. Therefore, understanding the way that the ligand stimulates the corresponding 
TLR is necessary to avoid undesirable side effect.  TLR signaling is distinguished to two 
pathways, MyD88 (myeloid differentiation primary response protein 88) dependent and 
MyD88-independent pathway. MyD88 is involved in all TLRs signaling with the 
exception of TLR3, which needs to bind with TRIF (TIR-domain-containing adapter 
protein-inducing IFN-β) for stimulation. The other TLR that uses TRIF adapter is TLR4, 
which is the first TLR described using TRIF to activate MyD88-dependent pathway.  
Although the regulation of TLRs is involved in the pathogenesis of various diseases, its 
application as a new therapeutic strategy is of great interest, as vaccine adjuvant 
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particularly. The type of immune responses elicited by various TLR ligands, specially the 
efficacy and safety of these agents are well reviewed 33. TLR7 and 8 that can be activated 
by synthetic imidazoquinoline derived compounds, such as imiquimod (R837) or 
resiquimod (R848) are focused here, since they have the advantage of activating both 
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), which augments the expression of 
co-stimulatory molecules (e.g. CD80, CD86), as well as triggers the production of IFN-α 
(Interferon-α) preferentially by TLR-7 on pDCs, and IL-12 by TLR-8 activation towards 
mDCs34. Moreover, type I IFN produced by pDCs can facilitate the direct priming of 
CTLs. In addition to targeting DCs, TLR7 or 8 activates nature killer (NK) cells to secret 
IFN-γ, and triggers B cells to produce Ig and cytokines. To date, most pre-clinical studies 
on TLR7/8 activation utilized R837 or R848 as the agonist. Though these two 
imidazoquinoline derivatives exhibit a similar molecular structure, only R848 can 
stimulate TLR7 and TLR8 simultaneously, making it more potent than R837.  
Pre-clinical studies demonstrate both agonists can enhance antigen specific T cell and B 
cell response, not only the magnitude but also the quality. Both in mice and non-human 
primate models, the delivery of R837 or R848 with HIV-1 Gag protein or plasmid 
enhanced T helper 1 (Th1) biases immune response, specially when the agonists were 
conjugated with protein35–37. Imiquimod alone or in the combination with HSV 
glycoprotein vaccine, significantly reduced the recurrence of HSV in guinea pig model, 
mostly correlated to the increased Interleukin-2 (IL-2) and antibody response38. The 
adjuvant potential of Resiquimod was also tested in chicken model, in which Resiquimod 
was found to augment both humoral and cellular response, by up-regulating the gene 
expressing of IFN (interferon)- α, IFN-β, IFN-γ, IL-1β, IL-4, and MHC II39. Beside the 
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direct injection of TLR7/8 agonists, the topical application of Imiquimod or Resiquimod 
at the injection site of peptide-based vaccine could also enhance antibody response, as 
well as CD4+ T cell response40,41. Furthermore, both Imiquimod and Resiquimod have 
been tested in the combination with cancer antigen NY-ESO-1 protein vaccine in patients 
with malignant melanoma, eliciting potent humoral and cellular responses in a significant 
fraction42,43. In general, TLR7/8 have been demonstrated as potent adjuvant for vaccine 
consisting of different immunogen, such as protein, DNA, peptide, and even DCs based 
vaccine.  	  
2.1.2 Nanoparticle	  based	  delivery	  system	  for	  vaccine	  design	  
Nanoparticles, which are defined as the particles with the size ranging from 1nm to 
1000nm44 , have been intensively studied in the development of subunit vaccines. In both 
prophylactic and therapeutic strategies, nanoparticles can efficiently deliver the antigens 
to specific immune cells, and /or act as immunostimulatant adjuvants to activate innate 
immunity. Based on the type of material, nanoparticles can be classified as liposomes 
(Fig.2-1A), polymeric nanoparticles (Fig.2-1B), inorganic nanoparticles (Fig.2-1C), and 
virus like particles (Fig.2-1D), self-assembling peptides and so on.  
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 Figure	  2-­‐1	  Schematic	  representation	  of	  different	  nanoparticles	  for	  antigen	  delivery	  (A)	  Liposome,	  (B)	  nanoparticles	  prepared	  from	  polymer,	  (C)	  gold	  nanoparticle,	  (D)	  virus	  like	  particle	  
2.1.2.1 Liposomes:	  
Liposomes are artificially prepared vesicles composed of a phospholipid bilayer shell 
with an aqueous core. As vaccine carries, liposomes have been used extensively to induce 
either CTLs response (cytotoxic T lymphocytes) or antibody titers (humoral immunity)45–
47 in vitro and in vivo 48,49. For vaccine formulation, an antigen (or adjuvant) may be 
encapsulated in the core of the liposome, buried within the lipid bilayers or adsorbed as 
well as chemically coupled on the surface 11,50.  
Based on the fact that the delivery efficacy of liposomes is affected by such factors as 
surface charge, vesicle size, phospholipid composition, lamellar structure 51, a large 
number of different approaches have been made to improve the immunoadjuvant activity 
of liposomes. The approaches include the modification of the liposome structures, the 
combination with other molecules such as immune potentiators, or conjugating with 
surface ligands for targeting to the DCs, a typical professional antigen presenting cells 
(APCs). Nakanishi et al. demonstrated that cationic liposomes were much more potent 
than anionic or neutral ones for generating cell-mediated immune response 52. An 
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interesting preclinical study done by Guan et al. revealed that liposome-associated (either 
encapsulated or surface-exposed) MUC1 peptide (BP25) produced a strong specific CTL 
response; however, a humoral response was only observed for the surface-absorbed BP25 
formulation 53. This suggests the strategy that is adopted for antigen loading has an 
impact on what sort of immune response is induced.   
Akira et al. demonstrated a highly efficient antiviral CD8+ T- cell induction by peptide 
epitopes chemically coupled to the surface of liposomes 54. This form of vaccination with 
a single epitope elicited antigen specific memory CD8+ T cell in the absence of CD4+ T 
cell help, which might had a potential advantage for the induction of antiviral immunity. 
As of 2008, there are two liposome-based vaccines in market, Epaxal for Hepatitis A, 
Inflexal V for influenza, which are both from Berna Biotech Company. Additionally,  
several liposome-based vaccines are under clinical study currently, for the intracellular 
infectious diseases, such as cancer and HIV-1.  
2.1.2.2 Polymeric	  nanoparticles:	  
Biodegradable polymeric nanoparticles have attracted much attention for biomedical 
applications, such as drug, gene, or vaccine delivery. The commonly used biodegradable 
polymers are aliphatic polyesters, including poly (lactic acid) (PLA), poly (glycolic acid) 
(PGA), poly (ε-caprolactone) (PCL), poly (lactide-co-glycolide) (PLGA). In particular, 
microsphere vaccine delivery systems based on PLA and PLGA 26,55,56 have been 
extensively investigated due to their long-term safety in humans, biodegradability, and 
the commercial availability of a variety of polymers of different molecular weights and 
monomer ratios 57,58. Similarly to liposomes, there are two main methods for antigen 
loading with polymeric nanoparticles, encapsulation and surface adsorption. The 
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encapsulation of antigens into PLGA NPs can be carried out by mainly three ways: the 
water-in-oil-in-water (w/o/w) emulsion technique59,60, the phase separation, and spray 
drying.   
To date, there have been many promising studies on different vaccine antigens 
encapsulated into PLGA nanoparticles shown to induce broad and potent immune 
response. For example, Chong et al. used PLGA nanoparticles (300nm) to load the 
hepatitis B core antigen (HBcAg) with or without monophospholipid A (MPLA) adjuvant 
61. A single immunization with HBcAg encapsulating NPs containing MPLA induced a 
stronger cellular immune response, compared with those induced by HBcAg alone or by 
physical mixture of HBcAg with MPLA.  Moreover, PLGA/antigenic peptide complex 
administrated by various routes, including oral, nasal and subcutaneous delivery, have all 
successfully generated potent CTL response, which suggests that PLGA particles can be 
taken up in vivo and cross-presented by resident APC62–64. In addition to the enhanced 
uptake, PLGA based delivery system is also observed to facilitate the endosomal escape 
of exogenous antigen and sustain the antigen level in cytosol of DCs to augment the 
cross-presentation efficiency65.  
However, these kinds of polymeric nanoparticles have some drawbacks, resulting from 
their hydrophobic nature, which would lower antigen encapsulation efficacy and higher 
burst effect of antigen release from NPs 66. To overcome these, a second hydrophilic 
component poly (ethylene glycol) (PEG) is introduced to form an ABA poly-D, L-
lactide-PEG 67,68.  
Beside of the modification of PLGA, recently, many studies have been focused on self-
assembled biodegradable nanoparticles fabricated by the amphiphilic block and graft 
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copolymers based on poly (amino acid) s, such as poly (α-L-glutamic acid) 69, poly (L-
lysine) 70, poly (γ-glutamic acid) 71, poly (ε-lysine) 72, poly (L-aspartic acid) 73, poly (L-
arginine) 74 and poly (L-asparagine) 75 as hydrophilic segments, with poly (β-benzyl-L-
aspartate) 76, poly (γ-benzyl-L-glutamate) 77, or poly (L-histidine) 78 as hydrophobic 
segments. Poly (γ-glutamic acid) (γ-PGA) is a naturally occurring poly (amino acid) 
synthesized by certain strain of Bacillus, which itself is poorly immunogenic 79–81, but has 
good resistance against many proteases. Nanoparticles composed of hydrophobically 
modified γ-PGA, in which γ-PGA acts as the hydrophilic backbone with L-phenylalanice 
(Phe) as the hydrophobic segment, are prepared as antigenic protein or peptide delivery 
system 14. Antigen-loaded γ-PGA-Phe based nanoparticles show an exciting strategy for 
the enhancement of antigen-specific humoral and cellular immune response through 
selective targeting of the antigen to APCs 82,83. It has been observed that the γ-PGA NPs 
are also effective for vaccines against human immunodeficiency virus (HIV-1) 84, 
influenza virus 85, Japanese encephalitis virus 86, or cancer 87,88.   
2.1.2.3 Inorganic	  nanoparticles:	  
Many inorganic materials, such as gold nanoparticles (AuNPs), or silica based 
nanoparticles (SiNPs) have also been used as vehicles for antigen delivery, offering the 
advantages of rigid structure and controllability over the synthesis, including size, shape, 
and surface properties. As vaccine delivery platform, AuNPs have been studied for the 
antigens derived from respiratory syncytial virus89, foot-and-mouth disease90, or DNA 
vaccine for HIV-191. By coating West Nile virus on AuNPs with different shapes 
(spherical, rod, cubic) and size range (2-150nm), the influence of shape and size of 
AuNPs on immune response in vitro and in vivo was investigated, in which 40nm sphere 
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was found optimal for antibody production92. For the development of cancer vaccines, 
AuNPs are found to promote significant antigen specific response without additional 
adjuvants, leading to subsequent anti-tumor activity and prolonged survival in both 
prophylactic and therapeutic in vivo tumor models93,94.  
The other promising inorganic material for vaccine design is silica. Despite the tunable 
particle size and shape, the abundant silanol group on the particle surface can contribute 
to the further modification with antigens, targeting moieties. Compared with solid SiNPs, 
mesoporous SiNPs (such as SBA-15 or MCM-41) with uniform pore size and ordered 
pore structures have higher loading capacity owning to their larger surface area, and 
perform better in control release of the cargos44. Furthermore, up to 30mg 
unfunctionalized mesoporous SiNPs were nontoxic when administrated subcutaneously, 
and only trace amount of mesoporous silicates were detected after 2 months95. Benefiting 
from these attributes, mesoporous SiNPs with the size ranging of 50-200nm have been 
applied as nanocarriers for protein based antigen via encapsulation and/or absorption96–100. 
It is also reported that SBA-15 can induce potent antibody response, independently of 
immune cell committed, while OVA loaded MCM-41 elicits both antibody and cellular 
response, with the latter one as dose-dependent98,99.  
2.1.2.4 Virus	  like	  particles	  (VLPs):	  
VLPs that resemble viruses, but do not contain any viral genetic materials, are prepared 
from the self-assembly of viral structure proteins, such as Envelope, or Capsid. 
Benefiting from the ideal particle size and repetitive display of virus surface proteins that 
present conformational viral epitopes, VLPs can induce both B cell and T cell immune 
response in the absence of adjuvant101. VLPs based vaccine is the first nanoparticle based 
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vaccine class in market, with the first product (hepatitis B vaccine) commercialized at 
1986. In 2006 and 2011, another two VLPs based vaccines were licensed for human use, 
for papillomavirus and Hepatitis E, respectively. In addition to the direct use of VLPs as 
immunogen, they are ideal carriers for the delivery of epitopes16,102, DNA targeting other 
diseases, with potency in stimulating humoral and cellular response. For epitope delivery, 
the particular VLPs structure is readily taken up into APCs, and thus prime long lasting 
CTL response, as well as potent antibody response. Remarkable work has been done with 
the hepatitis B core particles, human papillomavirus VLPs and parvovirus VLPs 
displaying T cell specific epitopes from other proteins on their capsid103–105. It is 
demonstrated that VLPs are efficient stimulators of MHC class I and class II responses106. 
Though the antigenic peptide can be exposed on the surface of VLPs by rational design of 
vaccine, the requirement of capsid to self-assemble often limit length of the foreign 
sequences incorporated into VLPs106.  
2.1.3 Cross-­‐presentation	  of	  exogenous	  antigen	  by	  DCs	  
Based on the presentation pathway, antigens can be classified as endogenous ones, which 
can be presented on the surface of all nucleated cells in the complex with MHC (major 
histocompatibility complex)-I molecules, and exogenous antigens processed and 
presented through MHC-II pathway. To prime CD8+ T cell response that is critical in the 
immunological control of tumor and infectious diseases, exogenous antigens need to be 
internalized from extracellular environment and presented as MHC-I bounded peptide, 
which process is termed “cross-presentation”. The principal cells that have this capacity, 
are dendritic cells and macrophages107,108, although in some circumstances various other 
cells, e.g. B cells109, neutrophils110 as well as endothelial cells111. Most studies indicate 
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that DCs are the most important cross-presentation APCs (antigen presenting cells) in 
vivo even though it is not unclear which DC subtypes can or cannot cross-present 
antigens.   
 The phenomenon of cross-presentation was firstly found by Bevan112 that in animals 
immunized with fully allogenic cells, part of the CTLs were generated specifically for 
minor antigens from the graft presented on MHC-I molecules of the host. The cross-
presented antigens can be acquired in several different forms, including DNA or 
RNA113,114, peptides, peptide-HSP (heat-shock proteins) complexes113,114, or as protein 
107,115,116, and, most importantly, cellular antigens117–119. Different forms of antigens 
would be internalized and cross-presented by APCs under distinct mechanisms. To date, 
two main intracellular pathways for cross-presentation have been reported, “cytosolic” 
and  “vacuolar” pathways120.  
The “cytosolic” pathway is sensitive to proteasome inhibitors, indicating the internalized 
antigens access the cytosol, where they are degraded into oligopeptides, which can then 
feed into endoplasmic reticulum (ER) by transporter associated with antigen processing 1 
(TAP1) and TAP2, through the classical MHC-I mediated presentation pathway.  In ER, 
proteasome generated oligopeptides are further trimmed by ER aminopeptidase-1 
(ERAP1) and endosomal insulin-responsive aminopeptidase (IRAP) to 8-mer or 9-mer 
peptides, for complex with MHC-I molecules and transporting to the cell surface for 
display.  By contrast, the “vacuolar” mechanism for cross-presentation is resistant to 
proteasome inhibitors and generally independent of TAP, but is sensitive to inhibitors of 
lysosomal proteolysis120. This suggests both antigen processing and binding with MHC 
class I molecules take place in endocytic compartments in this pathway.  
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The capacity of DCs to cross-present antigen is not only dictated by the characteristics of 
DC subtypes, but also influenced by additional factors, including mode of antigen 
internalization, formulation of antigens, as well as DCs’ maturation status121. Antigens 
can be internalized by DCs via various mechanisms, including non-specific, receptor-
independent pathway, such as pinocytosis and phagocytosis, as well as specific, receptor-
dependent processes, like uptake through C-type lectin receptors (CLRs), Fc receptors, 
and scavenger receptors, among which CLRs are considered as ideal candidate for the 
targeting of antigens to DCs. Dendritic cell-specific intracellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) is a paradigmatic example of CLRs expressed on 
human mucosal and dermal DCs, which facilitates rapid antigen uptake and processing 
for efficient cross-presentation. In most of recent studies, monoclonal antibody122 and 
natural CLR ligands (glycan)123 are intensively applied as targeting agents against DC-
SIGN. In addition, as another important CLR, mannose receptor (MR) targeting by two 
glycan ligands of MR, 3-sulfo-Lewis A and N-acetylglucosamine conjugated OVA 
antigen shows improved uptake by bone marrow derived DCs (BMDCs), resulting in 
enhanced cross-presentation in vivo124. With different receptor mediated internalizations, 
antigens would be routed to distinct endocytic compartments, determining cross-
presentation efficiency, possibly by influencing antigen translocation to cytosol. Mellman 
group compared the internalization and endosomal degradation of receptor bounded 
antigen by human DCs, by conjugating antibodies against different DCs receptors that 
were targeted to early or late endosomes, with CD40 and mannose receptor against early 
endosome, whereas DEC205 for late compartments125.  Their results showed, the peptide 
conjugated with the antibody targeting CD40 had the highest cross-presentation 
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efficiency, even though this antigen was least internalized by DCs. Additionally, 
inhibiting the antigen degradation in the late endosome rescued the DEC205 targeted 
cross-presentation, suggesting the internalization of antigen into the late compartments 
would impair the cross-presentation. The understanding of cross-presentation is crucial 
for the design of vaccine that aims to prime protective immunity against infectious 
diseases.  
2.1.4 Rational	  design	  for	  formulating	  peptide	  based	  vaccine	  
A primary goal of vaccine design is to find an optimal formulation to induce potent and 
long memory humoral and cellular responses to protect against specific diseases. There 
are a variety of considerations that need to be made during the incorporation of the three 
components for peptide-based vaccine: antigenic epitope, adjuvants (immune potentiator) 
and delivery platform (as shown in Fig.2-2).  
First and foremost among them is the selection of epitopes in terms of antibody response 
and/or cellular response from targeted pathogen. Though the humoral responses in 
sufficient quantity are predominant protective correlate, the cellular immunity is critical 
in the protection against intracellular infections, and in most diseases, the help from 
CD4+ T cells is necessary for the generation of effector B cells126. A vaccine that 
stimulates CD8+ T cells has been considered as a promising strategy to prevent infections 
with HIV-18. Moreover, the stimulation of CD4+ T cells is required to generate memory 
CTLs, even though some adjuvants such as TLR agonist can provide inflammatory 
cytokines to prime potent CTL response127. Thus, the epitope selection for broad-
spectrum HIV-1 vaccine may have to be directed towards not only highly conserved CTL 
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epitopes,	   but also helper T cell epitopes from the same protein.	  
	  
Figure	   2-­‐2	   Ideal	   formulations	   of	   peptide	   based	   vaccine,	   depending	   on	   the	   expected	   immune	  response:	  cellular	  or	  humoral	  response.	  
The formulation strategy for the association of antigens to the carriers is another factor 
that will affect the efficiency of artificial vaccines. The association has been achieved 
mainly through adsorption, encapsulation, and conjugation. Adsorption of antigen to the 
surface of inorganic particle-based delivery system is generally driven by electrostatic or 
hydrophobic forces26,128,129.  However, this kind of interaction between antigens and 
carries is relatively weak, which may lead to the rapid dissociation of cargoes from 
nanoparticles in vivo. By contrast, encapsulation or conjugation with chemical bond can 
provide stronger interaction, which are widely applied in the attachment of antigen to the 
delivery vehicles based on VLPs106, polymeric nanoparticles13, or liposomes51. In 
encapsulation, antigens are added to the nanoparticle precursor solutions before assembly 
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process and located in the interior of particles, in which a fraction of antigens might be 
lost causing relatively low loading efficacy. The complete and stable association of 
antigenic peptides to nanocarriers can be easily achieved by direct conjugation, which 
usually utilizes cleavable chemical bonds for the release of epitopes at the targeting 
location, such as peptide bond10, disulfide bond130.  
Besides, the size of vaccine particle can influence the biodistribution and the uptake 
mechanism, which subsequently affects the type or the level of resulting immune 
response. All particle used in vaccine formulations usually have a comparable size (<5µm) 
to the pathogens recognized by immune system, and internalized by APCs with different 
mechanisms depending on the respective size. When vaccine particles are administrated 
subcutaneously, small particles (20-200nm) can take free-drainage to the lymph node 
(LN), to be internalized by either LN-resident DCs, or macrophages, while larger 
particles (500-2000nm) need DCs or macrophages at the inject site to transport them to 
LN131. By using model polystyrene particles ranging from 20 to 2000nm, it is found that 
smaller particles (<500nm), in particular 40-50nm are preferentially taken up by DCs, 
and are significantly more able to promote CD8 and CD4 type I cellular responses, while 
large particles (>500nm) are mainly internalized by macrophages to induce a 
considerable antibody response132. No consensus exits about a specific size range for all 
vaccine formulations, but controlling the size of particles can be one promising means to 
passively target APCs, especially LN resident DCs, or to bias the immune response.  
Aside from size, the incorporation of an additional immune potentiator into the system, 
can further enhance the immunogenicity of the antigen, though some nanoparticle based 
delivery systems themselves already have the capacity of stimulating immunity133–136. It 
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is also suggested that for an efficient vaccine, the antigen and adjuvant should be 
processed by the same APC simultaneously137.  In fact, the antigen and TLR agonist 
should co-localize in the same phagosome for the efficient MHC II antigen 
presentation138.  
Furthermore, as the primary APCs processing and cross-presenting exogenous antigens to 
prime CTL response, targeting antigen to DCs is an intensively explored concept to 
reduce the required antigen dose and improve the cellular immunity. Thus it appears 
logical to combine DCs targeting with the co-delivery strategy to provide particular DC 
subtypes with both antigen and TLR agonist. Despite the passive targeting strategy by 
tuning the precise size of the vaccine formulation, active receptor-dependent targeting has 
also been intensively investigated, as discussed above. Additionally, since most 
nanoparticle based vaccines are internalized by DCs within the endosomal compartments, 
where the antigens are degraded impairing the cross-presentation efficiency, the 
endosomal escape of antigens to cytosol of DCs is another concern to enhance the CTL 
response. To achieve efficient cytosolic delivery of antigen, nanoparticle based delivery 
system is further harnessed with the moiety capable of membrane interruption, such as 
cell penetrating peptide139–141, pH-responsive polymers134.  
Combining the factors discussed above, the optimal formulation of peptide-based vaccine 
is illustrated as shown in Fig. 1, though there is no exactly ideal strategy for the design of 
all vaccines, which vary in the type of targeting diseases, the defined immune responses, 
and the administration routes. To date, the main challenge is the peptide-based vaccines 
have been slow to reach commercialization, largely due to safety concerns regarding the 
adjuvants and insufficient efficiency causing low clinical benefit rate. The new adjuvants 
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or delivery system is on demand, which should be evaluated more comprehensively and 
systematically.  
2.2 Self-­‐assembling	  peptide	  
Self-assembly is defined as the autonomous organization of components into ordered 
patterns or structures142. In the past decades, variable biocompatible and bioactive small 
molecules have been used as building blocks for self-assembling materials, such as 
nucleic acids, carbohydrates, or amino acids. Among them, amino acids that are the 
molecular units for proteins or peptides provide the widest feasibility of functionalization 
and modification, as well as cell signaling capacity. Inspired from the basic 
conformational structures (α helix, β sheet and turn, or coiled coils) existing in natural 
proteins, small peptides can be rationally designed to assemble to different kinds of 
supramolecular structures as fibers143–145, rods146,147, tubes148, micelles149, and 
globules150,151.  
2.2.1 De	  novo	  design	  principles	  for	  self-­‐assembling	  peptide	  
Though each artificially synthesized self-assembling peptide has its unique design 
strategy, the general rules underlying their design can be summarized as one of the 
combinations of the following factors: molecular amphiphilicity, structural compatibility, 
and environmental responsiveness. Large research efforts have been targeted on the de 
novo design principles for predicting structures from primary sequence152,153. Frederix et 
al. applied computational approach to screen all possible combinations (8,000 in total) of 
amino acids in tri-peptides and subsequently identified those with the best-predicted 
properties for experimental characterizations, demonstrating a methodology to predict the 
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self-assembling properties of tri-peptides152. Our group presents a systematic and simple 
design principle of amino acid pairing (AAP) for constructing functional supermolecules 
with peptide as the building block. In the principle, three main side chain interactions, 
including hydrophobic interaction, electrostatic attraction, and hydrogen bonding were 
discussed154. Based on this principle, our group designed and synthesized various self-
assembling peptides, for the delivery of either hydrophobic drug154 or hydrophilic small 
interferon RNA (siRNA)155. Both the computational and empirical principles provide a 
“bottom-up” engineering route for the design of artificial self-assembling peptides with 
predictable nanostructures for various applications.     
2.2.2 The	  application	  of	  self-­‐assembling	  peptide	  	  
Combining with biocompatibility as well as the ease of synthesis and functionality, the 
flexible construction of nanostructures makes the self-assembling peptide as an attractive 
biomaterial in the applications of regenerative medicine17, tissue engineering18,156,157 , 
drug delivery158, and vaccine design10,159, which are further reviewed in the following 
subsections.  
2.2.2.1 Drug	  delivery	  
In the delivery of biological molecules, such as DNA, siRNA, or hydrophobic drugs etc., 
self-assembling peptide acts as a promising approach, by encapsulation or co-assembly. 
Yang et al. developed a novel class of self-assembling peptide that formed core-shell 
structured nanoparticles (sequence: cholesterol-G3R6YGRKKRRQRRR). This peptide 
exhibited a broad-spectrum of antimicrobial activities against a variety of wild or drug-
resistant Gram-positive bacteria, fungi and yeast at low inhibitory concentration160. They 
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also synthesized an oligopeptide amphiphile containing three blocks of amino acids (Ac-
(AF)6-H5-K15, termed as FA32) that self-assembled into cationic core-shell micelles with 
the average diameter of 102nm, and evaluated its potential as a carrier for the co-delivery 
of Doxrubicin (DOX) and p53 gene. FA32 was found to encapsulate DOX at the loading 
capacity up to 22%, which further efficiently condensed p53 to small complex with net 
positive charge on the surface. A synergistic effort in end point cytotoxicity was observed 
by the sustained release of hydrophobic DOX and negatively charged p53161. For nuclei 
acid delivery, Zhang and coworkers designed a series of surfactant like peptides, in which 
there are repetitive hydrophobic amino acids, such as Alanine (A) or Leucine (L) as the 
tail, and positively charged amino acids at the terminal. These peptides self-assembled to 
nanovesicles or nanotubes, showing potential application for DNA delivery162. Moreover, 
the drug release concerns can also be beneficial from harnessing the self-assembling 
peptide with the stimuli-responsive properties, such as pH163, temperature154, ant other 
factors164.  
2.2.2.2 Vaccine	  design	  
During the application of self-assembling peptides as the scaffolds for regenerative 
medicine, or drug delivery, they have been found to be minimally immunogenic in animal 
models, even conjugating with the sequences derived endogenous proteins165–168. This 
feature is clearly an advantage as delivery platform for the application of vaccine design, 
especially for the peptide based vaccines, since either solid phase peptide synthesis or 
recombinant protein expression can easily conjugate the selected epitopes with self-
assembling sequence. Thus, nanoparticles based on self-assembling peptides have 
attracted considerable attentions in the design of peptide vaccines. 	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Burkhard and his group designed a novel type of nanoparticles (synthetic virus like 
particles) with regular icosahedral symmetry and with a diameter at about 16nm, which 
were formed by a polypeptide chain consisting of a pentameric coiled coil and a trimeric-
coiled coil. They extended the C-terminus of the trimeric coiled coil with either 
Pseudomonas 159or Severe acute respiratory syndrome (SARS) epitope19, and evaluated 
the immunogenicity in rabbit or mice, which demonstrated that protective antibodies 
were elicited without the use of adjuvant and the immune response was conformation-
specific. The formation of SARS epitope (red labeled) loaded peptide nanoparticle was 
simulated by computer model as shown in Fig.2-3.  Similarly, a self-assembling coiled-
coil lipopeptide was developed to form synthetic virus-like particles, which induced 
potent humoral response in rabbit as well169. Besides of the coiled-coil peptide as the 
building block for self-assembly, a simpler method that conjugating a di-alkyl tail with a 
CTL epitope at the N-terminal was presented and the formed cylindrical micelles offered 
in-vivo protection from tumors by stimulating the antigen specific CTLs165.  
 
Figure 2-3 (A) 3D monomeric building block of P6HRC1 composed of a pentameric coiled coil domain 
from COMP (green) and trimeric de novo designed coiled-coil domain (blue) that is extended by a 
sequence of SARS HRC1 epitope (red). (B) Computer models of the peptide nanoparticle and the 
calculated molecular weight. TEM of the nanoparticles was shown. (Adapted from reference19 with 
permission from the journal) 
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Moreover, a short fibrillization peptide, Q11 (Ac-QQKFQFQFEQQ-Am) that self-
assembled in salt-containing aqueous environment and formed networks of β-sheet rich 
nanofibers was designed and intensively investigated for displaying functional amino 
acid sequences or chemical groups by Collier and coworkers170,171. As shown in Fig.2-4, 
when Q11 was conjugated with a model epitope OVA323-339 containing bother T cell and 
B cell epitopes, the formed nanofibers displayed the epitopes on the surface and elicited 
antibody response in a comparable level to the epitope delivered in complete Freund’s 
adjuvant (CFA)10. They found this augmented antibody response was long-lived with the 
duration up to 40 weeks, and T cell- and MyD88-dependent, but self-assembling peptide 
type-independent172,173.   
 
Figure 2-4 (A) Schematic and sequence of epitope-bearing self-assembling peptide O-Q11; (B) O-Q11 self-
assembled into long, unbranched fibers; (C) O-Q11 elicit more potent OVA specific humoral response than 
epitope alone or the mixture of epitope and Q11 (Adapted from reference10 with permission) 
Moreover, even the self-assembling peptide Q11 emulsified in CFA, no detectable 
antibody was raised in mice. These findings suggest self-assembling peptide based 
nanoparticles have the capacity of enhancing the antibody response of antigenic peptides, 
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possibly owning to the repetitive display of B cell epitopes on the surface of 
nanostructure, which directly stimulated B cells more efficiently. However, for the CTL 
epitope, which requires to be processed and presented by DCs to prime or stimulate T 
cells, the efficient cross-presentation of exogenously delivered epitope is more critical for 
the induction of potent CTL response.  The feasibility of self-assembling peptide for the 
delivery of the CTL epitope has not been well studied or understood.  
2.2.3 Ionic-­‐complementary	  self-­‐assembling	  peptides	  
The ionic-complementary peptides are characterized by the periodic repeats of alternating 
charged hydrophilic and hydrophobic amino acids, the fist member of which was firstly 
discovered by Zhang from Z-DNA binding proteins174. The ordered charge distribution in 
the sequence leads to the unique electrostatic attractions between oppositely charged 
residues, which drives the self-assembly of peptides, combining with other interactions, 
such as hydrophobic interaction, hydrogen bonding. There are three types of charge 
distribution most widely studied among ionic-complementary peptide: type I, -+; type II, 
--++; type IV, ----++++175. In addition to the charge distribution, other factors such as 
secondary structure, concentration, pH, and salt effect influence the self-assembly of the 
peptides. To date, there are many ionic-complementary peptides have been studied, 
which are derived from either segments of natural proteins, or rationally design, as 
summarized in the review paper by Zhang S.175. Owing to the well-organized nanofiber 
structure and great water content (over 99%), the ionic-complementary peptides have 
been widely used for tissue engineering or scaffolds for 3D cell culture18. Our group 
investigated the mechanism whereby they undergo self-assembly, as well as the 
application in 3D cell culturing and drug delivery.    
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EAK16-II is a typical ionic-complementary self-assembled peptide, composed of 16 
amino acids (AEAEAKAKAEAEAKAK), forms β-sheet rich nanofibers of separated 
hydrophobic and hydrophilic faces in aqueous solution. The EAK16-II nanofibers were 
not only resistant to acid and proteases, but also non-immunogenic in mice174, which 
features were critical for the application in antigen delivery. Previous data suggested it 
could efficiently stabilize hydrophobic molecules as pyrene or anticancer drug ellipticine 
by non-covalent interaction176,177, demonstrating the potential in drug delivery.  
Moreover, Zheng and coworkers linked six consecutive histidines at the C-terminus of 
EAK16-II, which displayed the anti-polyhistidines antibodies (anti-CD4 antibody) on the 
surface of nanofibers, to engage T cells in vivo178.  Thus, EAK16-II based nanofibers 
offer the possibility of delivery short peptide or hydrophobic molecules, which could be 
helpful in the formation of peptide based vaccines.  
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Chapter	  3 Ex	  vivo	  generated	  Dendritic	  cells	  pulsed	  
with	  HIV-­‐1	  CD8+	  T	  cell	  epitope-­‐loaded	  self-­‐assembling	  
nanofibers	  elicited	  more	  potent	  CD8+	  T	  cell	  response	  
 
Abstract 
To focus CD8+ T cell response on the highly conserved epitopes has been considered as 
an effective strategy to overcome the extensive variability of HIV-1 proteins, which is a 
major obstacle for the development of HIV-1 vaccine. However, these antigenic peptides 
induce weak immunogenicity by themselves, thus require proper adjuvants to enhance the 
efficiency. We conjugated a self-assembling peptide EAK16-II with an HIV-1 CD8+ T 
cell epitope SL9. The new peptide SL9-EAK16-II self-assembled to short nanofibers in 
aqueous solution, which were stable in PBS or cell culture medium. The nanostructure 
efficiently protected the epitope SL9 from degradation in sera or inside DCs. Ex vivo 
generated dendritic cells pulsed with these nanofibers stimulated significantly more SL9-
specific CD8+ T cells. The results from confocal microscopy and flow cytometry 
demonstrated this enhancement in cellular response was mostly due to the sustained 
antigen level in the cytoplasm of DCs. Our finds suggested EAK16-II offered a potential 
as delivery vehicle for peptide based vaccine for HIV-1.  
 
3.1 Introduction	  
To date, no therapeutic or prophylactic Human Immunodeficiency Virus-1 (HIV-1) 
vaccine is yet available. A major hurdle is the high variability of HIV-1, which impairs 
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the efficiency of vaccines. One potential approach to overcome it is to induce broad 
cytotoxic T lymphocytes (CTL) response against multiple conserved epitopes in HIV-1 
proteins8,179. Several in-vivo studies with direct administration of peptide or peptides 
mixture have shown enhanced T cell response and reduced viral loading, however, rare 
overall clinical response from these peptide vaccines is observed so far180–183. This might 
ascribe to: 1) in vivo, direct binding of short peptide (8-10 amino acids for CLT epitope 
sequence) into class I major histocompatibility complex (MHC) could occur on not only 
professional antigen presenting cells (APCs), but also numerous other cells causing 
immune tolerance towards the epitopes184; 2) rapid degradation by tissue or serum 
peptidases was another concern in the weak immunogenicity of peptide antigen185,186. 
Thus, proper adjuvants or delivery systems that can protect the antigen from degradation, 
and facilitate the uptake and processing by dendritic cells (DCs) without any undesirable 
side effects are required to boost peptide specific immune response.  
The self-assembling peptide based delivery system, which has been intensively studied in 
the applications of regenerative medicine17, drug delivery154,187,188, tissue 
engineering18,156,158, and vaccines10,15,173,189–191 can provide various advantages, such as 
stability, biocompatibility, ease of synthesis and manufacturing, as well as controllability 
over nanoscale positioning of ligands. Particularly in the vaccine design, more advanced 
evidences from animal work have proven direct conjugation of  the epitope with the self-
assembling peptide can elicit potent and long term lasting antibody response, via the 
ordered and repeating display of B cell epitopes on the surface of nanostructures10,159,192–
194. However, to prime potent CTL response, exogenously administrated antigen is 
necessarily processed and cross-presented by APCs to stimulate CD8+ T cells. Whether 
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the cross-presentation efficiency of peptide-based antigen would be enhanced by the self-
assembling peptide was unknown.  
Therefore, to answer this question, we conjugated a self-assembling peptide EAK16-II 
(AEAEAKAKAEAEAKAK) with an HIV-1 specific CD8+ T cells epitope SL9, and 
determined the cellular response induced by the conjugating peptide SL9-EAK16-II. The 
peptide EAK16-II is an ionic complementary peptide that in aqueous solution 
spontaneously assembles into nanofibers or macroscopic membrane, driving by 
intermolecular hydrogen bonding, hydrophobic interaction from Ala (Alanine), and 
electrostatic interactions between Glu  (Glutamic acid) and Lys (Lysine)195.  The 
nanostructure formed by EAK16-II was stable in the presence of proteases, or in the 
solutions of extreme pH174. And SL9, an HLA-A*0201(A2)-restricted CTL epitope 
derived from HIV-1 P17 protein was tested, since it is highly conserved across circulating 
HIV-1 strains worldwide, and it produces a dominant SL9-T cell response in 75% 
chronically HIV-1 infected HLA-A2 positive adults 196–199 . The conjugated peptide SL9-
EAK16-II was found to spontaneously assemble into short nanofibers, which were more 
stable than SL9 with the presence of sera or inside DCs. The ex-vivo generated DCs 
pulsed with these short nanofibers stimulated significantly more SL9-specific CTLs, 
which might associate with the sustained antigen level in the cytoplasm of DCs. Our 
results indicated the self-assembling peptide EAK16-II could act as a platform for the 
design of HIV-1 peptide vaccine.  
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3.2 Materials	  and	  Methods	  
3.2.1 Materials	  
All peptides were synthesized with the solid phase peptide synthesis method, and purified 
by RP-HPLC in the lab. Peptide synthesis reagents were purchased from AApptec. The 5-
FAM labeled peptides were purchased from CanPeptide (Montreal, CA). Peptide 
solutions for nano-structure characterization such as AFM, TEM were prepared in pure 
Milli-Q water (18.2MΩ; Milli-Q system), with sonication of 15 minutes in water bath, 
and then allowed to self-assemble at room temperature overnight.  
Complete DC medium: serum-free DC medium (CellGenix, Portsmouth, NH) 
supplemented with 800U/mL GM-CSF, 1,000U/mL IL-4 (R&D system), 100U/mL 
penicillin, 100µg/mL streptomycin, and 2mM L-glutamine (Life technology); Complete 
RPMI-1640 medium (R10): RPMI1640 (Life Technologies) supplemented with 10% 
human AB serum (Sigma), 100 U/ml penicillin, 100 µg/mL streptomycin, and 2mM L-
glutamine; DC maturation cytokine cocktail: 5ng/mL (final concentration) TNF- α  (R&D 
System), 5ng/mL IL-1β (R&D System), 1µg/mL prostaglandin E2 (Sigma, Oakville, ON, 
Canada), and 150ng/mL IL-6 (R&D System); Dyes used in sample preparation for 
confocal microscope: Lysotracker Deep red, Nucblue Live Ready probes reagent (Life 
technology) 
Subjects Five HLA-A2 HIV-1 infected individuals were recruited under a protocol 
approved by the ethics committee at St. Michael’s hospital, Toronto, an affiliate of the 
University of Toronto. Written consent was obtained from all 5 participants. Among 
these 5 subjects, one was a long-term non-progressor (asymptomatic, untreated HIV-1 
	   39	  
infection for more than 10 years with CD4+ T cell count=970/mm3 and viral load 
(VL)=118 RNA copies/mL), one was a treated chronic infection (infected for more than 1 
year with more than 1 year of continuous anti-retroviral therapy (ART) before sampling, 
CD4+ T cell count=460/mm3 and VL=49 RNA copies/mL), and three were untreated 
chronic infection (infected for more than 1 year without prior ART, mean CD4+ T cell 
count=473/mm3, range=380-560/mm3 and VL=137,563 RNA copies/mL, range=10,215-
373,361 RNA copies/mL ). Our collaborator M.D. Mario Ostrowski and M.D. Jun Liu 
carried out this work.  
3.2.2 Methods	  
Peptide synthesis and purification All peptides were synthesized with Apex396 parallel 
synthesizer on Rink Amide resin (AApptec, KY) using standard Fmoc-based solid phase 
peptide synthesis. Briefly described, the deprotection of Fmoc from amino acid was 
accomplished by the treatment with 20% piperidine in DMF (N, N-dimethylformamide), 
followed by coupling with activated carboxyl group of next amino acid, using 
HCTU/DIEA as coupling reagent. After the synthesis, the raw peptide products were 
cleaved from resin with conventional trifluoroacetic acid (TFA)/ triisopropylsaline 
(TIS)/H2O cocktails, and collected by precipitation into the cold methyl t-butyl ether. 
Then the peptides were purified on Waters 600E HPLC, with acetonitrile (0.1% TFA) 
and water (0.1% TFA) as eluents. The pure products were confirmed with mass 
spectrometry (Appendix Fig.1-3), and stored at 4°C.	  Potential lipopolysaccharide (LPS) 
contamination in all peptide solutions for in-vitro study was checked with Chromogenic 
LAL Endotoxin Assay Kit (GenScript, Piscataway, NJ) according to manufacturer’s 
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protocol. LPS in all peptide preparations was negligible (less than 0.007 EU LPS/µg 
peptide). 
Surface tension measurement Axisymmetric drop shape analysis-profile (ADSA-P) was 
used to measure the surface tension of the peptide solutions as previously reported200. The 
peptide solutions were prepared in pure Milli-Q water, at various concentrations ranging 
from 0.005mg/mL to 0.7mg/mL. The very low concentrations (<0.10mg/mL) were 
obtained by preparing 0.15mg/mL peptide stock solution in THF, adding the stock 
solution of a calculated volume into the glass vial, evaporating the solvent, and then 
adding 1mL of pure Milli-Q water, which was followed by sonication for 10mins in a 
water bath.  
Circular Dichroism (CD) spectra Far-UV circular dichroism spectra of the peptide 
samples were measured at room temperature using a Jasco J-815 CD spectrometer 
(Tokyo, Japan). 150µL peptide solution was scanned in a 0.1cm quartz cell from 190 to 
250nm. The water spectrum was used as the baseline for data collection. The final 
spectrum shown here was an average of three independent measurements.  
Morphology characterization with Atomic Force Microscopy (AFM) and 
Transmission Electron Microscopy (TEM) Atomic force microscopy was used to 
determine the nano-structures of peptide self-assemblies. 100µL peptide solution was 
dropped on the surface of a freshly cleaved mica sheet for various times ranging from 
5mins to 30mins, depending on the concentration of solutions. Then the free peptide was 
removed by blotting, and washed with 300µL pure water. After air-dry, AFM imaging 
was carried out at room temperature using the Peak Force tapping mold on a Dimension 
Icon AFM (Bruker, Santa Barbara, CA).  To confirm the structures acquired from AFM, 
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TEM was also utilized. 10µL peptide solution was applied to a 400 mesh Formvar coated 
copper grid for 3-5 minutes, followed by negative staining with 10µL 2% uranyl acetate, 
blotted drying, and analysis on TEM (Philips CM10 TEM, operating at 60KeV). 
Particle size measured by dynamic light scattering (DLS) The hydrodynamic diameter 
of the sample was measured using DLS on a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK) equipped with a 4mW He-Ne laser operating at 633nm. 50µL solution was 
added in low volume disposable polystyrene cuvette and the scattered light intensities 
were collected at an angle of 173°. Three independent measurements were performed to 
generate the intensity based size distribution profile. 
Serum stability assay Peptide stabilities were carried out in fetal bovine serum (FBS). 
FBS was centrifuged at 13000 rpm for 10mins to remove lipids and the supernatant was 
collected and diluted in DPBS to obtain 10% (volume percentage), 50%, and 100% FBS, 
which would be incubated at 37°C for at least 10min before the assay. 100µM peptide 
stock solutions, including SL9 or SL9-EAK16-II were prepared separately as described 
above. The assay was initiated upon the addition of peptide to the serum for a final 
concentration at 23 µM. The incubation time points were taken as 15, 30, 60, 90 and 120 
min, followed by the precipitation of proteins with trichloroacetic acid (TCA) at a final 
concentration of 10%. The mixture was then kept at 0°C for 10mins for complete 
precipitation. The suspension was then centrifuged at 13000 rpm for 10mins, in which the 
supernatants were taken out and analyzed on RP-HPLC. The analysis was run on Waters 
600E HPLC, using a linear gradient of 10%-60 % solvent C (0.1% TFA in acetonitrile) in 
25mins. The retention time for each peptide was determined by the peptide solution in 
DPBS for a final concentration of 23 µM (which equals to the final concentration adopted 
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for the in-vitro studies) as control at 0 min. The peptide remaining in FBS at each time 
point was calculated with the area of peptide peak in Waters 2487 dual UV detector at 
215nm as a percentage of the area of the 0 min DPBS treated peptide peak. Each 
experiment was performed in triplicate. The raw data from HPLC was shown in 
Appendix 1.  
Peptide degradation in thimet oligopeptidase (TOP) Hydrolysis of the peptide in TOP 
(Abcam, Toronto, CA) was carried out as previously described201. Briefly, 23µM peptide 
was incubated at 37°C for various time intervals with 46nM TOP in 100µL 50mM 
Tris/HCl buffer (pH 7.8, 2mM MgCl2, 0.1mM dethiothreitol). The reaction was stopped 
with 10µL acetic acid, which was further assessed with the amount of intact peptide using 
RP-HPLC, as described above.  
Ex-vivo Generation of monocyte-derived dendritic cells (MDDCs) Peripheral blood 
mononuclear cells (PBMCs) were isolated from the whole blood from the donors, using 
Ficoll-Hypaque gradient centrifugation media (GE healthcare life science, Mississauga, 
Canada), which was conducted by our collaborator Jun Liu (M.D.) in University of 
Toronto.  Monocytes were then isolated from PBMCs with Human Monocyte Isolation 
Kit-II (Miltenyi, San Diego, CA) and cultured in complete DC medium (as described in 
material subsection) for 5 days to generate immature MDDCs. The purity of the obtained 
MDDCs was determined with flow cytometry. For the analysis, the MDDCs were stained 
with fluorophore labeled anti-human HLA-DR and anti-human CD1a mAbs 
(eBiosciences) as two surface markers for DCs.   
Fluorescent peptide tracking in MDDCs SL9 and SL9-EAK16-II were labeled with 5-
carboxyfluorescein  (5-FAM) at the N-termini. Immature MDDCs were pulsed with 5-
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FAM-SL9, mixture of 5-FAM-SL9 and EAK16-II, 5-FAM-SL9-EAK16-II or culture 
medium R10, then maturated with the cytokine cocktails (as described in material 
subsection). After 12hrs, the MDDCs were thoroughly washed with PBS to remove the 
free peptides, which were then re-cultured in fresh medium. At various time intervals, the 
MDDCs were collected and analyzed with flow cytometry (BD LSRII, BD). The live 5-
FAM+ MDDCs were quantified with FlowJo (Treestar, Ashland, OR). 
Intracellular location of antigen in MDDCs To investigate the intracellular distribution 
of peptide, 106 immature MDDCs were cultured with 5-FAM-SL9 or 5-FAM-SL9-
EAK16-II (the final peptide concentration was kept at 15µM) at 37°C for 4 hours, which 
were then thoroughly washed with PBS to remove the free peptides. Immediately or 12h 
after the peptide loading, the cells were stained by 75nM Lysotracker Deep red for 0.5hr, 
and washed with PBS, followed by re-cultured in fresh medium. Prior to being observed 
under confocal microscopy, one drop of Nucblue Live Ready probe reagent was added 
per well and incubated for 10mins to stain DCs’ nuclei. All images were acquired using 
Zeiss LSM700 laser scanning confocal microscope. The co-localization coefficient 
between 5-FAM and Lysotracker Red channels was calculated by ImageJ software with 
the Menders Coefficients plugin. 20 cells were counted for each sample.  
SL9-specific CTL response Immature MDDCs were seeded in 96-well plate with 105 
cells in 50µL complete DC medium per well. Then, the MDDCs were pulsed with SL9, 
EAK16-II, mixture of SL9 and EAK16-II, or SL9-EAK16-II at the concentration of 
23µM, with culture medium R10 (described in the material subsection above) as blank 
control, and further activated with DC maturation cytokine cocktails (described in the 
material subsection above). After 24h, the supernatants and cells were harvested. The 
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collected MDDCs were washed thoroughly 3 times with complete RPMI-1640 medium 
and then co-cultured with autologous PBMCs at 1:10 ratio in medium R10 for 7days. The 
PBMC were then re-stimulated with autologous Epstein-Barr virus (EBV)-immortalized 
B cells (prepared by our collaborator) that were pre-treated by SL9 in advance. After 6h 
incubation, the PBMCs were stained with fluorophore labeled SL9-tetramer, anti-human 
CD3, anti-human CD8, anti-Interferon-γ (IFN-γ), anti-Tumor necrosis factor-α (TNF-α) 
and anti-CD107a mAbs (eBiosciences), which was followed with the analysis on flow 
cytometry (BD LSRII, BD). The frequency of CD8+ T cells binding with SL9-tetramer 
or expressing IFN-γ, TNF-α and CD107a was quantified with FlowJo (Treestar, Ashland, 
OR). Isotype control antibodies were used as gating control.  
Statistic analysis The one-way analysis of variance (ANOVA) was used for the 
comparison between multiple groups, with the software Prism (version 6) (Graphpad 
software, SD, USA). P <0.05 was considered as significant. 
3.3 Results	  
3.3.1 SL9-­‐EAK16-­‐II	   self-­‐assembled	   to	   stable	   nanofibers	   in	   aqueous	  
solution	  or	  cell	  cultural	  medium	  
For the work reported here, we utilized the self-assembling peptide EAK16-II to 
conjugate in tandem with SL9, between which a hydrophilic spacer Ser (Serine)-Gly 
(Glycine)-Ser-Gly was inserted, leaving the epitope domain positioned at the N-terminus, 
as shown in Fig.3-1. When dissolved in water at the concentration up to 3.0mM, no 
visible precipitate was observed.  AFM and TEM were used to investigate the 
morphology of SL9-EAK16-II aggregates before or after addition to cell culture medium. 
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As shown in Fig (3-2a, 3-2b), SL9-EAK16-II self-assembled to short nanofibers 
(~1.37nm for height and ~8.04nm for width) of various lengths, but mostly shorter than 
150nm, as well as some globules with the diameter ranging from 10 to 20nm; while 
adding to the medium, the peptide was visualized as short nanofibers predominately, 
without any further aggregation or dissociation (Fig. 3-2c, 3-2d). From the CD spectra as 
shown in Fig. 3-3a, the secondary structure analysis of SL9-EAK16-II indicated a 
transition from a β-sheet rich structure (minimal ellipticity at 208nm) for EAK16-II to α-
helical conformation (minimal ellipticity at 206nm and 222nm), while SL9 itself was 
unstructured random coil. Similar transition was observed when EAK16-II was appended 
with H6 domain178. The conformational structure of the peptide was not critical when 
eliciting CTL response, but could be important for B cell epitope, especially 
conformational B cell epitope to induce antibody response23.
	  
Figure 3-1The molecular structure of SL9-EAK16-II was simulated with Hyper Chem software, displaying 
carbon atom with black, nitrogen atom with cyan, oxygen atom with white, and the secondary structure 
shown as red ribbon. 	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Figure 3-2 AFM (a) and TEM (b) for 100μM SL9-EAK16-II in water; the morphology of 23μM SL9-
EAK16-II self-assemblies in cell culture medium was also characterized with AFM (c) and TEM (d). 
Before added with peptide solution, the medium was treated by 10000rpm centrifugation of 30mins and 
filtration with 0.1μm syringe filter to remove the big particles including lipid and proteins.  
As an important parameter in controlling the stability of peptide aggregates, the critical 
assembly concentration (CAC) of SL9-EAK16-II was measured by surface tension 
method. As shown in Fig.3-3b, when the peptide concentration increased, the surface 
tension dropped dramatically down to a minimum value, and then it slightly increased to 
a plateau. The CAC of SL-9-EAK-16-II was estimated at around 0.02mg/mL (~7µM), 
which was much lower than the one of EAK-16-II itself (0.10mg/mL or 62µM)202. The 
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low CAC would prevent the nanostructure from dissociation at the injection site by the 
dilution effect from body fluid. 
	  
Figure 3-3 CD spectra of the peptides including epitope SL9, EAK16-II, and SL-EAK16-II (a); the 
equilibrium surface tension of SL9-EAK16-II was plotted versus peptide concentration (b), from which its 
critical assembling concentration (CAC) was estimated. 	  	  
In addition to the concentration effect, the ubiquitous existence of salts in physiological 
environment would also influence the assembly behavior of the ionic complementary 
self-assembling peptides202. Thus, we determined the stability of SL9-EAK16-II 
nanofibers in PBS for various time intervals, which were monitored with DLS and AFM 
for hydrodynamic size and morphology respectively. As shown in Fig. 3-4a, the 
hydrodynamic size of SL9-EAK16-II aggregates in water was around ~44nm, while 
added to PBS, the size slightly increased to ~68nm; after one day, the hydrodynamic size 
of the particles increased to ~103nm, however, which did not further change significantly 
during the following 7-day’s storage at 4°C (Fig.3-4b).  
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Figure 3-4 Hydrodynamic size distribution of SL9-EAK16-II nanoparticles in water or PBS was measured 
by DLS (a); the stability of the nanoparticles in PBS stored at 4 was monitored with DLS  (b) for up to 
7days. 
	   49	  
	  
Figure 3-5 AFM images of SL9-EAK16-II self-assemblies in PBS at day 0 (a) or day1. 
The short nanofibers in PBS at day0 (Fig.3-5a) or day1 (Fig.3-5b) were similar to the 
ones observed in pure water, but with less globular particles, suggesting that the addition 
of salt would facilitate nanofiber forming. The width and height of the nanofibers in 
different solutions were further quantitatively analyzed using Gwyddion software on 
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AFM images, as summarized in Table 3-1. With the exception of the peptide in PBS at 
day1, the heights of the aggregates in water (~1.37nm), culture medium (~1.32nm) or in 
PBS at day0 (~1.28nm), were consistent with the theoretic diameter of an α-helix (1.2nm, 
including side chains), which implied that the helical peptide monomers assembled side 
by side to form monomolecular layered structure. In comparison, the height of short 
fibers in PBS at day1 was almost doubled to ~2.64nm, possibly resulting from the stack 
of two molecular layers, which might contribute to the increased hydrodynamic size 
measured by DLS. Overall, SL9-EAK16-II formed stable nanofibers either in the aqueous 
solution with or without salt, or in culture medium, which was a desirable characteristic 
for an ideal peptide-antigen delivery system44. 	  
Table 3-1 Quantitative analysis of particles on AFM images for SL9-EAK16-II self-assemblies in different 
solvents 
 Water Medium PBS (day0) PBS (day1) 
Height (nm) 1.37 ± 0.15 1.32 ± 0.16 1.28 ± 0.11 2.64 ± 0.20 
Width (nm) 8.04 ± 1.21 7.70 ± 1.23 9.15 ± 1.60 9.78 ± 1.78 	  
3.3.2 Self-­‐assembling	   SL9-­‐EAK16-­‐II	   showed	   higher	   resistance	   to	  
extracellular	  proteases	  or	  intracellular	  peptidase 
We compared the degradation rate of SL9 and SL9-EAK16-II in the buffers consisting of 
different content of FBS, by tracking the remaining amount of peptide with RP-HPLC 
after various incubation times, as summarized in Fig. 3-6(A-C) for 10%, 50% and 100% 
FBS, respectively. For SL9 alone, it was degraded rapidly by FBS, with half-life 
decreasing from 30mins to 10mins when FBS content in buffer increased from 10% to 
100%; after 2 hours, almost rare SL9 could be detected. In contrast, the degradation of 
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SL9-EAK16-II in serum proceeded at a significantly slower rate leaving ~70% peptide 
detectable in 100% FBS after an incubation time of 2 hours.   
	  
Figure 3-6 Stability comparisons between SL9 and SL9-EAK16-II in 10%FBS (A), 50% FBS (B), 100% 
FBS (C), and thimet oligopeptidase (TOP) (D). The intial concentration of peptide at fixed at 23µM, while 
the molar ratio of peptide to TOP was at 500:1. 
Afterwards, we further determined the degradation fate of these two peptides with the 
presence of an intracellular peptidase, thimet oligopeptidase (TOP) that was found as a 
primary cytosolic oligopeptidase in DCs to destroy antigenic peptide and limit the extent 
of MHC I antigen presentation in vivo201,203. As show in Fig. 3-6D, SL9 was hydrolyzed 
quickly by TOP with ~17% remaining after 2 hours incubation, while the self-assembling 
SL9-EAK16-II was more persistent in TOP, leaving approximately 80% peptide intact 
after 2 hours. This significant stability of SL9-EAK16-II in TOP implied the 
nanostructure could sustain the antigen level in the cytosol, which could prolong the 
cross-presentation of exogenous antigen by DCs to stimulate T cells.  
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3.3.3 SL9-­‐EAK16-­‐II	  induced	  stronger	  SL9	  specific	  CTL	  response	  than	  SL9	  in	  
vitro.	  	  
  
Figure 3-7 Ex-vivo generated MDDCs were treated with different antigens, including R10 (blank control), 
EAK16-II, SL9, mixture of SL9 and EAK16-II, and SL9-EAK16-II for 24h, which then co-cultured with 
PBMCs from HLA-A2 HIV-1 infected patents for additional 7days. SL9-specific CTL response were 
revealed by SL9-tetramer and intracellular cytokine staining with flow cytometry. The data was shown as 
the frequency of CTLs binding SL9-tetramer (a), or expressing IFN-γ (b), TNF-α (c) or CD107a (d).  The 
experiments were carried out with PBMCs from 5 HIV-1 infected patients. *: p≤0.05, **: p ≤ 0.01,  ***: p 
≤ 0.001. 
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These physicochemical characterization results confirmed the stable nano-fibrillar 
structure effectively protected the loaded epitope from degradation. To examine if this 
enhanced stability would be beneficial to recall the SL9 specific CTL response, we tested 
the efficiency of the MDDCs pulsed with different antigens to stimulate CD8+ T cells. 
Ex-vivo generated MDDCs were treated with SL9, EAK16-II, the mixture of SL9 and 
EAK16-II or SL9-EAK16-II, and then co-cultured with autologous PMBCs, which was 
followed by re-stimulation with SL9-pulsed autologous EBV-immortalized B cells as 
targeting cells. The antigen specificity of the activated CD8+ T cells was determined by 
staining the cells with fluorophore labeled SL9-tetramer. The frequency of SL9-tertramer 
positive CD8+ T cells was quantified with flow cytometry. As shown in Fig. 3-7a, the 
MDDCs pulsed with SL9-EAK16-II stimulated more SL9-specific CD8+ T cells than the 
ones treated with other antigens. The functionality of the SL9 specific CTLs was further 
assessed. The frequency of SL9-specific CTLs that expressed IFN-γ, TNF-α, or CD107a 
was measured and shown in Fig. 3-7 (b-d). SL9-EAK16-II stimulated significantly more 
functional CTLs than either SL9 or EAK16-II. Furthermore, the mixture of SL9 with 
EAK16-II did not bring about any improvement in CTL response compared to SL9 alone, 
suggesting the peptide bond linking between SL9 and EAK16-II was critical for the 
enhanced CTL response.  
	   54	  
3.3.4 SL9	  in	  nanostructure	  form	  was	  more	  persistent	  in	  MDDCs	  	  
	  
Figure 3-8 MDDCs were pulsed with 5-FAM-SL9-EAK16-II, 5-FAM-SL9, mixture of 5-FAM-SL9 and 
EAK16-II, or medium R10 as blank control, which were further maturated with cytokines cocktail. After 
12h, MDDCs were thoroughly washed to remove the free peptides, and further tracked 5-FAM+ MDDCs 
after certain intervals with flow cytometry (a). The data point was shown as mean ± SD (n=3). A 
representative flow cytometry profile from one experiment is provided (b).  
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To determine whether the enhancement in CTL response facilitated by SL9-EAK16-II 
nanofibers was associated with prolonged presentation by DCs, the persistence amounts 
of fluorophore labeled peptides inside DCs were tracked over time. MDDCs were pulsed 
with 5-FAM labeled SL9, SL9-EAK16-II or the mixture of 5-FAM-SL9 and EAK16-II 
for 12 hours, which were then thoroughly washed to remove the free peptides. At certain 
time, the MDDCs were analyzed by flow cytometry for intracellular fluorescence level, 
which was summarized in Fig.3-8. Immediately after peptide loading, SL9 either alone or 
conjugating with EAK16-II was taken up efficiently by MDDCs (almost 90% 5-FAM+ 
DCs), which did not show significant difference in the percentage of 5-FAM+ MDDCs. 
24 hours later, the amounts of the peptides remaining inside MDDCs decreased 
dramatically, however, more SL9-EAK16-II remained in MDDCs. After 80 hours’ 
incubation, SL9-EAK16-II was still detectable in ~3.33% MDDCs. 
3.3.5 SL9-­‐EAK16-­‐II	   more	   efficiently	   escaped	   from	   endocytic	  
compartments	  to	  cytosol	  
Though short synthetic CTL epitope is possibly cross-presented by DCs via directly 
extracellular binding with MHC I expressed on the surface of DCs204, extensive 
experimental evidences suggest the exogenous antigens are necessarily processed in 
cytoplasm to be efficiently cross-presented205. Therefore, confocal microscopy was then 
utilized to observe the intracellular distribution of 5-FAM-SL9 or 5-FAM-SL9-EAK16-II 
inside DCs at different time intervals. Immature MDDCs were loaded with 5-FAM 
labeled SL9 or SL9-EAK-16-II for 4 h, which were washed thoroughly, then stained with 
Lysotracker deep red to label acidic organelles (endosome and lysosome) immediately or 
after additional 12h incubation.  
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 Figure	  3-­‐9	  MDDCs	  were	  pulsed	  with	  5-­‐FAM	  labeled	  peptides,	  and	  maturated.	  After	  4h,	  MDDCs	  were	  washed	  with	  PBS	  to	  remove	  the	  free	  peptides,	  and	  observed	  under	  confocal	  microscopy	  immediately	  (panels	  labeled	  as	  0h)	  or	  re-­‐cultured	  in	  fresh	  medium	  for	  another	  12h	  (panels	  labeled	  as	  12h).	  Prior	  to	  microscopy,	  acidic	  organelles	  were	  stained	  by	  Lysotracker	  deep	  red,	  and	  nuclei	  were	  stained	  with	  NucBlue.	   The	   co-­‐localization	   coefficients	   between	   green	   and	   red	   channels	   were	   calculated	   with	  ImageJ	  software	  based	  on	  20cells	  per	  sample.	  	  
As shown in Fig. 3-9, both 5-FAM-SL9 and 5-FAM-SL9-EAK16-II were internalized by 
MDDCs efficiently, however, the intracellular distributions varied. For the DC pulsed 
with the epitope, the fluorescent peptide was observed in both acidic compartments 
(stained with red fluorescence) and cytoplasm, suggesting both endocytosis and direct 
entry mechanism involved in the uptake. After 12 hours, the fluorescent intensity from 
the peptide faded, leaving only weak fluorescence observed and located in endo-
lysosomes. By contrast, the 5-FAM-SL9-EAK16-II was taken up by MDDCs mainly 
through endocytosis pathway, indicated by the co-localization coefficient (>0.8) between 
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the red and green channels; with further incubation, the co-localization coefficient 
decreased to almost 0.2, suggesting the peptide escaped from the endo-lysosomes to the 
DC’s cytosol. This endosomal escape implied a cytosolic cross-presentation mechanism 
for the conjugating peptide134. 
3.4 Discussion	  
In this study, we demonstrated that directly conjugating an HIV-1 CTL epitope SL9 with 
self-assembling moiety EAK16-II significantly enhanced the immunogenicity of the 
epitope in vitro.  Our results suggested this enhancement mostly benefited from the 
prolonged cross-presentation of the exogenous epitope which was delivered to the 
cytoplasm of DCs by the self-assembling peptide.  
By solid phase peptide synthesis, the epitope SL9 was easily loaded with the fibril 
forming sequence (EAK16-II). Physicochemical characterizations including morphology 
and CAC, demonstrated the addition of the epitope into the EAK sequence did not impair 
the self-assembling behavior, though altered the secondary structure from β-sheet to α-
helix. A similar transition was observed when EAK16-II was conjugated with other 
sequences; however, no mechanism has been proposed to explain it. From the initial 
computer modeling of the EAK sequence, a helical structure was suggested, in which the 
side chains of glutamic acids and lysines provided electrostatic interaction to stabilize the 
conformation206. Moreover, after conjugation, the amino acid flanking the N-terminus of 
the peptide changed from Alanine to Serine. The side chain of Serine but not Alanine 
could form hydrogen bond with the free NH group of peptide helix (from the first four 
residues in helix), which might also stabilize helix formation in peptide207. More precise 
explanation could be obtained with molecular simulation.  
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The nanostructure formed from the conjugating peptide protected the epitope from the 
proteolytic degradation, thus could be conserved for longer time (up to 72h) inside 
mature MDDCs. It was reported when PLGA microparticles were loaded with ovalbumin 
(OVA), they served as intracellular antigen reservoirs, providing sustained MHC class I 
presentation up to 96h, which was described as a major advantage over soluble antigen65. 
This prolonged antigen presentation has been shown highly correlated with the enhance T 
cell response in-vitro and in vivo208,209. Moreover, the process time for professional APCs 
such as DCs to encapsulate the exogenous antigen in peripheral and migrate to lymphoid 
tissues has been estimated last to 24-48h210. Before the antigen loaded DCs contact with 
T cells in lymphoid tissues, to keep the quantity of epitope-MHC complexes on DCs 
above certain level plays an important role for the potent stimulation towards T cells.  
Therefore, the prolonged antigen cross-presentation of the conjugate peptide could 
contribute to the augmented immunogenicity.  
Furthermore, our confocal microscopy results implied the conjugating peptide SL9-
EAK16-II underwent a different presentation pathway from the epitope SL9. Depending 
on the binding affinity, two distinct pathways for exogenous epitope loading to MHC I 
molecule have been demonstrated, as direct binding on the surfaces of APCs, or 
internalization and loaded with MHC I molecules in endoplasmic reticulum (ER), with 
the latter one involved in the cross-presentation of SL9 to CTLs204,211. Consistent with 
these reports, our finds suggested that SL9 would be internalized by DCs through both 
endocytosis and direct penetration into cytoplasm. Moreover, the fraction of SL9 inside 
endosomal compartments did not escape to the cytosol. By contrast, SL9-EAK16-II 
nanofibers were dominantly internalized to endosomal compartment, and subsequently 
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escaped to the cytoplasm. The endosomal escape of epitope-bearing nanofibers implied a 
cytosolic pathway for the cross-presentation of SL9-EAK16-II, which was suggested as 
more efficient120. The liposome leakage assay (Appendix Fig.4) illustrated different 
membrane permeability for the two peptides: At pH7.0, SL9 caused more leakage, 
however, this was abolished when pH decreased to 5.0, while the permeability of SL9-
EAK16-II was slightly decreased with lower pH. The different membrane permeability of 
SL9 at different pH values might explain the entrapment of SL9 inside endolysosomes 
after internalization. Moreover, the membrane disrupting activity was rarely discussed for 
the peptide EAK16-II or any peptide containing the same sequence as EAK16-II. From 
our results, the moderate membrane permeability of the SL9-EAK16-II promoted the 
endosomal escape of the antigen, but without causing cytotoxicity. Nevertheless, the 
mechanism of this membrane penetration remains unclear, which should be studied in 
future. These results show that EAK16-II can offer not only protection against extra-
/intracellular degradation that elongated the persistence of epitope inside DCs, but also 
enhanced endosomal escape for a more efficient cross-presentation pathway.  
However, the conjugating peptide SL9-EAK16-II did not show any maturation activity 
against MDDCs in-vitro, which might cause immune tolerance. Thus, the 
immunogenicity of SL9-EAK16-II was examined in the form of DC based vaccine, i.e. ex 
vivo generated MDDCs were pulsed with SL9-EAK16-II, further maturated with cytokine 
cocktails, and then used to simulate T cells. By contrast, several biodegradable materials, 
such as γ-PGA-Phe, PLGA nano- or micro-particles, liposomes, or cationic polystyrene 
microparticles, have been reported possessing the ability to maturate DCs13. However, the 
mechanism for the activation towards DCs from these materials remains unknown, and 
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even reverse results were observed for the same materials61. The self-assembling peptide, 
Q11, when coupled with a model peptide antigen from OVA, significantly enhanced the 
expression of CD80 and CD86 on DCs in vivo212. Since the conjugating peptide SL9-
EAK16-II exhibits a similar nano-fibrilar structure as OVA-Q11, we expect to observe a 
similar DC maturation property if SL9-EAK16-II was administrated into mice. Compared 
to this controversial self-adjuvanting strategy, the combination of TLR agonists with 
nanoparticle-based delivery system appears to be more promising for the design of 
peptide-based vaccine. Therefore, to harness SL9-EAK16-II with DC maturation activity, 
the incorporation of TLR agonist into the EAK-based system would be introduced in the 
following chapter.   	   	  
	   61	  
Chapter	  4 Self-­‐assembling	  peptide	  for	  co-­‐delivery	  of	  
HIV-­‐1	  CD8+T	  cell	  epitope	  and	  Toll-­‐like	  receptor	  7/8	  
agonists	  R848	  to	  induce	  maturation	  of	  monocyte	  
derived	  dendritic	  cell	  and	  augment	  polyfunctional	  
cytotoxic	  T	  lymphocyte	  (CTL)	  response	  
Abstract 
A peptide based vaccine that incorporates one or several highly conserved CD8+ T cell 
epitopes to induce potent cytotoxic T lymphocyte  (CTL) response is desirable for some 
infectious diseases, such as HIV-1 (human immunodeficiency virus-1), and cancers. 
However, the CD8+ T cell epitope is often weakly immunogenic, and thus requires a 
specific adjuvant or delivery system to enhance the efficiency. Here we investigated the 
use of self-assembling peptide EAK16-II based platform to achieve the co-delivery of 
CD8+ T cell epitope and TLR7/8 agonists (R848 or R837) for augmenting DCs 
maturation and HIV-1 specific CTL response. HIV-1 CTL epitope SL9 was conjugated 
with EAK16-II to obtain SL9-EAK16-II, which further spontaneously co-assembled with 
R848 or R837 in aqueous solution, forming co-assembled nanofibers. Fluorescence 
spectra and calorimetrical titration revealed the interaction between SL9-EAK16-II 
assemblies and R848 or R837 via hydrogen bonding and hydrophobic interaction, with 
the binding affinity (dissociation constant Kd) of 0.62 µM or 0.53 µM, respectively. 
Furthermore, ex vivo generated DCs from HIV-1+ patients pulsed with the SL9-EAK16-
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II/R848 nanofibers stimulated significantly more polyfunctional SL9 specific CTLs, 
compared to the DCs pulsed with SL9 alone or the mixture of SL9 and TLR agonist. Our 
findings suggest self-assembling peptide EAK16-II might be used as a new delivery 
system for peptide based vaccine.  
4.1 Introduction	  
Synthetic peptides have attracted considerable attention as antigens for subunit vaccine 
design, since they offer several advantages over live or attenuated pathogenic 
microorganisms, including lower risk of reverting to virulent form, ease of 
manufacturing, reduced cost, and more precise control of antigen specific immune 
response23,24. However, owning to the rapid degradation and lack of “danger signal” to 
maturate dendritic cells (DCs)184, it is particularly challenging for exogenously 
administrated peptide to induce potent cytotoxic T lymphocyte (CTL) response, which is 
considered to be critical for effective vaccination against some infectious diseases, such 
as Human Immunodeficiency Virus (HIV-1), hepatitis C, and cancers8,184. To address this 
issue, a common approach has been to use micro- or nanoparticles to co-deliver the 
antigens and the immnostimulatory molecules, such as toll like receptor (TLR) agonist to 
target the same DC, which have a synergistic effort in enhancing antigen specific CTL 
reseponse61,94,133–135,213.   
Self-assembling peptide is rapidly becoming a synthetic delivery platform of choice, 
which has been explored for a variety of biomedical and biotechnology applications, such 
as regenerative medicine17, tissue engineering18,156, and antigen delivery10,173,193.  In these 
applications, the self-assembling peptides provide several advantages, including 
biostability, biocompatibility, synthetic definition, and controllability over the structure 
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of nanoparticles. EAK16-II (AEAEAKAKAEAEAKAK), an ionic-complementary 
peptide, self-assembles into β-sheet rich nanofibers with separated hydrophilic and 
hydrophobic faces, driven by hydrophobic interaction from Alanine (A) and electrostatic 
interaction between oppositely charged Glutamine (E) and Lysine (K)174. The 
spontaneously organized nanofibers are resistant to acidic environment with the presence 
of proteases, without inducing immune response when injected into mice20,174. These 
characteristics make it ideal for protecting and delivering antigenic peptide to DCs. 
Moreover, as a delivery vehicle, EAK16-II can incorporate with cargos by either direct 
conjugation178, or co-assembling process via non-covalent interactions214.  Combing these 
two strategies, it provides an opportunity to achieve co-delivery of CTL epitope and TLR 
agonist.  
Therefore, in the current study, we conjugated EAK16-II with an HIV-1 specific CTL 
epitope SL9 to obtain SL9-EAK16-II, which further co-assembled with TLR7/8 agonist, 
R848 (Resiquimod) or R837 (Imiquimod) to form a tripartite formulation (CTL epitope, 
immune potentiator and delivery carrier). The co-assembly mechanism was investigated 
with fluorescence microscopy and calorimetric titration. The SL9 specific CTL response 
induced by the tripartite formulation was examined as a DC-based vaccine.  	  
4.2 Materials	  and	  Methods	  
4.2.1 Materials	  
All peptides were synthesized as described in previous chapter. Complete DC medium: 
serum-free DC medium (CellGenix, Portsmouth, NH) supplemented with 800U/mL GM-
CSF, 1,000U/mL IL-4 (R&D system), 100U/mL penicillin, 100µg/mL streptomycin, and 
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2mM L-glutamine (Life techenology); Complete RPMI-1640 medium R10: RPMI1640 
(Life Technologies) supplemented with 10% human AB serum (Sigma), 100 U/ml 
penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine; DC maturation cytokine 
cocktail: 5ng/mL (final concentration) TNF-α (R&D System), 5ng/mL IL-1β (R&D 
System), 1µg/mL prostaglandin E2 (Sigma, Oakville, ON, Canada), and 150ng/mL IL-6 
(R&D System); Dye used in samples preparation for confocal microscope: Lysotracker 
Deep red, Nucblue Live Ready probes reagent (Life technology)  
The materials and main procedures for in-vitro study in this chapter were similar as 
described in Chapter 3.  
4.2.2 Methods	  
Peptide/TLR ligand complex preparation The peptide was dissolved in Milli-Q water 
with 30mins sonication in water bath at room temperature and incubated overnight. Then 
TLR agonist (R837 or R848) was dissolved in THF at 2mM, which was pipetted into 
glass vials, followed by solvent evaporation. After the peptide solution was added, the 
mixture was stirred overnight. 
Morphology characterization with Atomic force microscopy (AFM) and 
Transmission electron microscopy (TEM) 50µL peptide or peptide/TLR agonist 
complex solution was dropped on the surface of a freshly cleaved mica sheet for 5mins. 
Then free sample was removed by blotting, and washed with 300µL pure water. After air-
dry of several hours, AFM imaging was taken at room temperature using the Peak Force 
tapping mold on a Dimension Icon AFM (Bruker, Santa Barbara, CA). Additionally, 
TEM was utilized to confirm the nanostructure visualized from AFM. Briefly, 10µL 
peptide solution was applied to a 400 mesh Formvar (with carbon reinforced) coated 
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copper grid for 3-5 minutes, followed by negative staining with 10µL 2% uranyl acetate, 
blotted drying, and analysis on TEM (Philips CM10 TEM, operating at 60KeV). 
ANS fluorescence assay 8-anilinonaphthalene-1-sulfonic acid (ANS) solution was 
prepared in a phosphate buffer (10mM, pH=6.0) at a concentration of 10µM, which was 
mixed with equal volume of the freshly prepared SL9-EAK16-II solution (0.10mM) or 
pure water. 70µL of the relevant solution was transferred to a quartz microcell and tested 
on the Photon Technology International spectrafluorometer (Type QM4-SE, London, 
Canada) with a continuous xenon lamp as the light source. The fluorescence spectra of 
ANS were collected from 420 to 670nm with the excitation at 360nm. The excitation and 
emission slit widths were set at 0.5mm and 1.25mm, respectively.  
Isothermal Titration Calorimetry (ITC) For all ITC experiments performed on Nano-
ITC (190µL, TA instruments, New Castle, DE) at 298K, Milli-Q water was filled in 
reference cell. 400µM SL9-EAK16-II was prepared in Milli-Q water with 30 mins’ 
sonication and followed by overnight incubation, while R837 or R848 was prepared at 
20µM by stirring overnight to dissolve completely, which was further adjusted pH to the 
same value as the one of the peptide solution (pH=6.0) using acetic acid. All solutions 
were degassed for 30mins, before 51µL of peptide solution was loaded into the syringe, 
and 300µL R837 or R848 was placed in the sample cell.  The syringe was set to a stirring 
speed at 250rpm, after equilibrium time for baseline acquirement, 31 injections were 
performed with 200s’ interval. The first injection volume was 1.0 µL and the heat signal 
was ignored in the data analysis so as to compensate the error generated from insertion of 
needle, leakage of the peptide solution from syringe, and so on; the following injections 
were set at 1.5µL volume each. Blank titrations of the peptides into water (pH was 
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adjusted to 6.0 with acetic acid) were performed to measure the heat of dilution of the 
peptide, which was subtracted from the integration data prior to curve fitting. Origin 8 
software was used to fit the heat profiles, assuming one-site binding. For each TLR 
ligand, the experiments were conducted three times.  
Fluorescence spectroscopy A Photon Technology International spectrafluorometer 
(Type LS-100, London, Canada) with a pulsed xenon lamp as light sauce was utilized to 
measure the fluorescence spectra of R837 or R848 to study the interaction between 
peptide and agonist. Samples (70 µL) were transferred to a quartz cell (1cm × 1cm), 
which were exited at 245nm for R837, 248nm for R848 respectively. The emission data 
was collected in the range of 300-450nm. Different volumes of SL9-EAK16-II solution 
were added to the fixed agonist concentration at 15µM to obtain peptide/agonist molar 
ratio from 0.5:1 to 6:1.  
Circular Dichroism (CD) spectrum Far-UV circular dichroism spectra were measured 
at 298K with Jasco J-815 CD spectrometer (Tokyo, Japan) for the secondary structure of 
peptide and peptide/agonist complexes.  150µL sample solutions were scanned in a 0.1cm 
quartz cell from 260nm to 190nm, with solvent spectrum as baseline for data collection. 
The raw CD ellipticity (in millidegree) was converted to molar ellipticity (deg cm2 dmol-
1). The results reported here were the averages of three replicates.   
Particle size measured by dynamic light scattering (DLS) The hydrodynamic diameter 
of sample was assessed by DLS on a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) equipped with a 4mW He-Ne laser operating at 633nm. 50µL solution was added in 
low volume disposable polystyrene cuvette and the scattered light intensities were 
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collected at an angle of 173°. Three independent measurements were performed to 
generate the intensity based size distribution profile.  
Ex vivo Generation of monocyte-derived dendritic cells (MDDCs) The procedure is 
similar as the one described in Chapter 3. Monocytes were isolated from peripheral blood 
mononuclear cells (PBMCs) with Human Monocyte Isolation Kit-II (Miltenyi, San 
Diego, CA) and cultured in complete DC medium for 5 days to generate immature 
MDDCs.  
Visualization of uptake of SL9-EAK16-II/R848 by Confocal microscope The peptide 
SL9-EAK16-II was labeled with 5-carboxyfluorescein  (5-FAM) at N-terminal, which 
then co-assembled with R848 or R837 as described above. Immature MDDCs were 
seeded in 4-well Lab-Tek chamber slide with 106 cells in 450µL complete DC medium 
per well and incubated at 37°C for 24h. Then, MDDCs were pulsed with 5-FAM-SL9-
EAK16-II/R848 for 0.5h, followed by staining the intracellular acidic organelles with 
Lysotracker Deep red. After additional 0.5h incubation, cells were washed with PBS and 
re-cultured in fresh medium. Before the visualization under confocal microscopy, one 
drop of Nucblue Live Ready probe reagents were added per well and incubated for 
10mins to stain DCs nuclei. All images were acquired using Zeiss LSM700 laser 
scanning confocal microscope. 
Maturation of MDDCs Immature MDDCs were collected and seeded in 96-well plate at 
37°C with 105 cells in 50µL complete DC medium per well, which were treated by SL9, 
the mixture of SL9 and EAK16-II or SL9-EAK16-II with the absence or presence of the 
agonists (peptide final concentration at 0.03mM), or DC medium as control. After 24h, 
	   68	  
the MDDCs were collected and stained with anti-human CD83 mAbs. The percentage of 
CD83 expressing cells in MDDCs was determined by flow cytometry.  
HIV-1 SL9 epitope-specific CD8+ T cell response Following the procedures described 
in Chapter 3, the ex-vivo generated MDDCs were pulsed with different antigens for 24 
hours, which were then washed thoroughly 3 times with complete RPMI-1640 medium, 
followed by co-culturing with autologous PBMCs at 1:10 ratio in medium for 7 days. The 
PBMCs were then stimulated with autologous EBV-immortalized B cells pulsed with 
SL9 for 6 h, stained with fluorochore labeled mAbs against human CD3, CD8, IFN-γ, 
TNF-α, and CD107a and acquired by a flow cytometer (BD LSRII, BD). CD8+ T cells 
expressing IFN-γ, TNF-α, and CD107a were quantified with FlowJo (TreeStar). Isotype 
control antibodies were used as gating control.  
Statistic analysis The two-way analysis of variance (ANOVA) was used for comparison 
between multiple groups, with the software Prism 6.0 (Graphpad software, SD, USA). P 
<0.05 was considered as significant.  
4.3 Results	  	  
4.3.1 SL9-­‐EAK16-­‐II	  /	  TLR	  agonist	  co-­‐assembled	  to	  nanofibers.	  
 As described in Chapter 3, we conjugated SL9 at the N-termini of fibril forming moiety 
EAK16-II, with a flexible spacer –Ser-Gly-Ser-Gly- in between. The second structure of 
SL9-EAK16-II was measured as α-helix (data shown in Chapter 3). This altered 
secondary structure might have an impact on the self-assembly mechanism of epitope-
bearing EAK16-II and its capability of delivering TLR agonists, since our previous works 
suggested EAK16-II stabilized hydrophobic compounds with the hydrophobic face of its 
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β-sheet microstructure176,215. Thus, prior to using the TLR agonist, we studied the 
hydrophobic character of the conjugated peptide with 8-anilinonaphthalene-1-sulfonic 
acid (ANS) as probe molecule, of which the fluorescence spectrum shifts towards lower 
wavelength (blue shift) with enhanced intensity in a less polar environment216. Fig.4-1a 
showed in pure water, the fluorescence spectrum of ANS had a peak located at ~524nm; 
by contrast, in SL9-EAK16-II solution, the emission maxima was blue-shifted to 
~482nm, and the intensity increased significantly, which demonstrated the conjugated 
peptide aggregated in aqueous solution and the formed nanostructure could provide a 
hydrophobic interior to stabilize hydrophobic compounds.  
 
Figure 4-1 The fluorescence spectra of ANS with or without the presence of SL9-EAK16-II (b); Molecular 
structures of TLR 7/8 agonist R848 (left) and TLR7 agonist R837 (right). 
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Then, we mixed the conjugated peptide with TLR agonist (R848 or R837 as shown in 
Fig. 4-1b) to form the complexes/co-assemblies of SL9-EAK16-II/R848 or SL9-EAK16-
II/R837, and employed fluorescence microscopy to investigate the interactions between 
the peptide and the agonist. The fluorescence spectra of R848 or R837 with the different 
peptide concentrations were determined. As presented in Fig. 4-2(upper), the 
fluorescence intensity of R848 increased with the addition of SL9-EAK16-II; upon the 
peptide concentration increasing, the intensities of the emission peaks located at ~327nm, 
~343 nm increased, while the emission intensity at ~356nm barely changed. This 
enhancement in the fluorescence intensity could be due to the less polar environment 
where R848 resided. To further analyze the data, the intensity ratio of R848 emission 
bands (I327/I343) was plotted as a function of the molar ratio between peptide and agonist 
(Fig.4-2 lower). It was obviously observed that the intensity ratio (I327/I343) increased with 
more peptide adding, which however approached a plateau from the molar ratio of 4:1. 
The intersection might indicate the molar ratio for the saturation binding between R848 
and SL9-EAK16-II, which was estimated as 3.28:1. The same method was applied to 
investigate the co-assembly between SL9-EAK16-II and R837. Since the two TLR 
agonists were both imidazoquinoline derivatives, the fluorescence spectra of R837 (Fig. 
4-3 upper panel) exhibited a similar pattern as those of R848, however, with the emission 
bands blue-shifted by 3nm. And the saturation binding between SL9-EAK16-II and R837 
was found at the molar ratio of 3.94:1 from Fig. 4-3(lower panel).   
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Figure 4-2 The fluorescence spectra (upper) of R848 with different concentrations of SL9-EAK16-II, in 
which the one for R848 in water was shown with dashed line. The emission intensity ratio I327/I343 was 
plotted versus the molar ratio of peptide over R848 (lower). The concentration of R848 was fixed at 15µM. 	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Figure 4-3 The fluorescence spectra (upper) of R837 with different concentration of SL9-EAK16-II, in 
which the one for R837 in water was shown with dashed line. The emission intensity ratio I324/I340 was 
plotted versus the molar ratio of peptide over R837. The concentration of R837 (lower) was fixed at 15µM.  
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Figure	  4-­‐4	  Calorimetric	  titration	  of	  peptide	  solutions	  into	  R837	  (Left	  panel)	  or	  R848	  (right	  panel)	  at	  298K:	   SL9-­‐EAK16-­‐II	  was	   titrated	   to	   R837	   (a),	   or	   R848	   (b);	   SL9	   to	   R837	   (c)	   or	   R848	   (d)	   The	   heat	  profiles	  was	  obtained	  by	  the	  integration	  of	  peaks,	   from	  which	  the	  heat	  generated	  in	  the	  titration	  of	  peptide	  into	  water	  was	  subtracted.	  	  
	   74	  
Table 4-1	  Thermal dynamic parameters (mean ± SD, n=3) of SL9-EAK16-II/TLR agonist binding obtained 
by ITC	  
 R837 R848 
ΔH (kJ mole-1) -28.43±0.63 -21.18±0.32 
ΔS (J mole-1 K-1）  24.94±2.18 47.8±0.86 
-TΔS (kJ mole-1) -7.43±0.65 -14.24±0.26 
Kd (µM) 0.53±0.02 0.62±0.06 
N 3.94±0.20 3.25±0.23 	  
To further understand the mechanism of the co-assembly, isothermal titration calorimetry 
(ITC) was utilized to determine the thermodynamic parameters (including stoichiometry 
N, dissociation constant Kd, ΔH, and ΔS) of the binding between the conjugated peptide 
and the TLR agonist. As shown in Fig.4-4 (upper panels), the injection of SL9-EAK16-II 
into R848 or R837 generated exothermic peaks, which were further integrated to obtain 
the heat released in each titration. The heat profiles were adequately fitted to one-site 
binding model (Fig.4-4 lower panels). The obtained thermodynamic parameters are listed 
in Table 4-1. The negative enthalpy change (-21.18 kJ/mole for R848, -28.43 kJ/mole for 
R837) and the positive entropy change (47.8 J/mole/K for R848, 24.94 J/mole/K for 
R837) indicated the binding process was favored by both enthalpy and entropy, which 
suggested except the hydrophobic interaction, hydrogen bonding also participated in the 
co-assembly process217. However, the enthalpic and entropic contributions for the two 
agonists binding with SL9-EAK16-II were slightly different. From R848 to R837, the 
enthalpy change (ΔH) decreased by 7.25kJ/mole, while the entropic contribution (-TΔS) 
increased by 6.81 kJ/mole, almost compensating the favorable change in the binding 
enthalpy. Thus, the resulting dissociation constants did not exhibit a remarkable 
difference: 0.62µM for R848 vs 0.53µM for R837 (Table 4-1), indicating that the agonist 
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binds SL9-EAK16-II with a similar affinity. This phenomenon is usually termed as 
enthalpy-entropy compensation, especially when the two ligands share a similar 
molecular structure as here R837 and R848 do218. Furthermore, the stoichiometry values 
calculated from the ITC data were consistent with the saturation-binding ratios estimated 
from the fluorescence spectra: 3.25 vs 3.28 for SL9-EAK16-II/R848, and 3.94 vs 3.94 for 
SL9-EAK16-II/R837. Therefore, the molar ratio of peptide to agonist was fixed at 4:1 
when preparing the peptide/agonist co-assemblies for the following experiments. 
By contrast, the titration profiles for epitope SL9 into the two agonists (Fig. 4-4c, d) 
demonstrated an endothermic process, and the heat change during titration was positive 
and chaotic, which implied the bindings between the epitope SL9 and the agonists were 
negligible. These results suggested the binding between SL9-EAK16-II with the agonists 
was dominantly due to the EAK16-II moiety, rather than the specific sequence from the 
CTL epitope.  
	  
Figure 4-5 Secondary structure of the peptide in the co-assemblies of SL9-EAK16-II /R848 or SL9-
EAK16-II /R837 was characterized with CD (a); the hydrodynamic size distributions of the co-assemblies 
were measure with DLS (b).  
The further characterizations for the co-assemblies of peptide/agonist at the molar ratio of 
4:1 were conducted. Fig. 4-5a presented the α-helical structure of SL9-EAK16-II in the 
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co-assemblies, indicating the addition of agonist did not alter the conformational structure 
of the peptide. Moreover, the particle size distribution of the co-assemblies was 
characterized with dynamic light scattering (DLS). As shown in Fig. 4-5b, the mean 
hydrodynamic diameter of the peptide/agonist co-assemblies was ~400nm for SL9-
EAK16-II/R848, and ~710nm for SL9-EAK16-II/R837.  
	  
Figure 4-6 AFM and TEM were used to characterize the structures of the co-assemblies: AFM image (a) 
and TEM image (b) for SL9-EAK16-II/R848; AFM (c) and TEM (d) for SL9-EAK16-II/R837. The scale 
bars represent 100nm.  
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The morphology of the co-assemblies was visualized by AFM and TEM, appearing as 
interweaved nanofibers, for SL9-EAK16-II/R848 (Fig. 4-6a and 4-6b), or SL9-EAK16-
II/R837 (Fig. 4-6c and 4-6d). We further analyzed the AFM images with software 
Gwyddion, obtaining the average width of the fibers, 9.2 ± 0.7nm, and 8.4 ± 0.9nm for 
SL9-EAK16-II/R848 or R837 respectively. This structural resemblance together with the 
similar binding affinity evidently suggested when the conjugated peptide SL9-EAK16-II 
co-assembled with R848 or R837, it followed the same mechanism.  In our proposed 
model as depicted in Fig. 4-7, the helical peptide molecules aggregated side by side, 
primarily driven by the electrostatic interaction between the side chains of glutamic acid 
and lysine, as well as the hydrophobic interactions provided by alanine and the non-polar 
amino acids in the epitope sequence; the agonist was buried and stabilized within the 
hydrophobic faces of the peptide helices, via hydrophobic interaction and hydrogen 
bonding, as suggested by the evidences from the study of fluorescence spectra and 
calorimetric titration. 
	  
Figure 4-7 The schematic illustration of the co-assembly between SL9-EAK16-II and the TLR agonist. 
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Collectively, the above results demonstrated EAK16-II could be used as a carrier to 
achieve the co-delivery of the antigenic peptide SL9 and the hydrophobic TLR agonists 
(R837 or R848) by direct conjugating or non-covalent interactions respectively. And the 
co-existence of the two cargoes in the fibril structure would facilitate the uptake of the 
antigen and immune potentaitor into the same phagosome of antigen presenting cells 
(APCs), which was critical for the efficient antigen presentation to T cells31,138,219. 	  
4.3.2 SL9-­‐EAK16-­‐II/R848	  aggregates	  were	  internalized	  by	  MDDCs	  through	  
endosomal	  pathway	  and	  activated	  MDDCs	  efficiently.	  	  
Since DCs are the most effective APCs, and in particular the main APCs for cross-
presenting exogenous antigens to T cells31, we evaluated the uptake and intracellular 
localization of SL9-EAK16-II/R848 nanofibers in MDDCs with confocal microscopy. 
The immature MDDCs were treated with 5-FAM-SL9-EAK16-II/R848 for 0.5h, which 
were further stained acidic organelles with Lysotracker deep red, and nuclei with Nucblue. 
As presented in Fig. 4-8a, fluorescence labeled nanofibers (green) were internalized 
MDDCs quickly and co-localized with lysotracker (red), suggesting the nanofibers were 
taken up to endosomal compartments, where TLR7/8 was mainly expressed33. Similar 
result was observed for SL9-EAK16-II/R837 (data not shown). 
Afterwards, we determined the efficiency of the peptide/agonist co-assemblies to 
maturate MDDCs. The immature MDDCs were pulsed with different antigenic 
formulations for 24 hours, and then the expression level of maturation marker CD83 on 
DCs were assessed with flow cytometry.  	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 Figure	   4-­‐8	   Confocal	   microscope	   was	   applied	   to	   study	   the	   intracellular	   localization	   of	   5-­‐fam-­‐SL9-­‐EAK16-­‐II/R848	  in	  MDDCs	  (a);	  Maturation	  marker	  CD83	  on	  DCs	  was	  stained	  and	  analyzed	  with	  flow	  cytometry.	  The	  data	  was	  shown	  as	  the	  percentage	  of	  CD83	  expressing	  cells	  in	  total	  MDDCs	  (mean	  ±	  SEM,	  n=3),	  with	   the	  MDDCs	  treated	  by	  medium	  as	  control	   (b);	  PBMCs	   from	  HLA-­‐A2	  HIV-­‐1	   infected	  individuals	   were	   co-­‐cultured	   with	   MDDCs	   that	   were	   already	   pulsed	   with	   different	   antigen	  formulations	   (medium	  as	   control),	   and	   then	   re-­‐stimulated	  with	  SL9-­‐pulsed	  autologous	  B	   cells.	  The	  secretion	   of	   IFN-­‐γ,	   TNF-­‐α,	   and	   CD107a	   were	   assessed	   by	   intracellular	   cytokine	   staining	   and	  polychomatic	  flow	  cytometry.	  	  The	  frequency	  of	  CD8+	  T	  cells	  secreting	  IFN-­‐γ	  (c)	  or	  the	  combination	  of	  IFN-­‐γ,	  TNF-­‐α,	  and	  CD107a	  (d)	  was	  presented	  (mean	  ±	  SEM,	  n=3).	  **:	  p	  ≤	  0.01,	  	  ***:	  p	  ≤	  0.001,	  ns:	  p	  >	  0.05.	  
Fig.4-8b shows the frequencies of CD83-highly expressing DCs stimulated by SL9, the 
mixture of SL9 and EAK16-II, or SL9-EAK16-II with the absence or presence of the 
TLR agonists. The peptides themself did not induce MDDCs maturation. By contrast, a 
notable up-regulation of cell surface marker CD83 was detected when MDDCs were 
treated with the peptide in the presence of R837 or R848. Since R848 was a more soluble 
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and potent analog of R837, which was reported to produce 50-to 100-fold cytokine 
response compared to R837220, when mixed with SL9 or the mixture of SL9 and EKA16-
II, R848 maturated more MDDCs than R837. However, the co-assemblies of SL9-
EAK16-II/R837 could induce up-regulation of CD83 to a similar extent as observed for 
SL9-EAK16-II/R848. Moreover, these two formulations maturated more MDDCs 
compared to SL9, or the mixture of SL9 and EAK16-II with the presence of R837 or 
R848. Taken together, these results demonstrated that the co-assembled nanofibers (SL9-
EAK16-II/R837 or R848) could be effectively taken up to endosomal compartments of 
MDDCs, and augmented the MDDCs maturation. 
4.3.3 DCs	  pulsed	  with	  SL9-­‐EAK16-­‐II/R848	  nanofibers	  elicited	  significantly	  
stronger	  SL9	  specific	  CD8+	  T	  cell	  response.	  	  
Having demonstrated that the TLR agonist delivered within the nanofibers induced potent 
DCs maturation, we further determined if the SL9 sequence that was conjugated with the 
self-assembling peptide could be efficiently processed and presented to CD8+ T cells, 
using an MDDC-T cell co-culture system. The ex-vivo generated MDDCs were loaded 
with different antigenic formulations for 24h, followed by co-culturing with autologous 
peripheral blood monocytes (PMBCs) for 7days. PBMCs were then re-stimulated for 6h 
with autologous B cell line that was pulsed with SL9 peptide in advance.  The CD8+ T 
cells co-expressing IFN-γ+, TNF-α+, and CD107a+ in response to the SL9 re-stimulation 
were then measured with flow cytometry. As shown in Fig. 4-8c, the MDDCs pulsed with 
SL9-EAK16-II/R848 nanofibers stimulated significantly higher percentage of IFN-γ 
expressing CD8+T cells, when compared to those treated with SL9, or the mixture of SL9 
and EAK16-II in the absence or presence of the TLR agonists. Recent data suggested the 
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simultaneous expression of multiple cytokines could provide a better picture of CTLs 
functional quality221,222.  Fig. 4-8d presented the frequency of these so-called 
polyfunctional (IFN-γ+, TNF-α+, and CD107a+) SL9 specific CTLs. SL9-EAK16-
II/R848 nanofibers consistently stimulated more polyfunctional CTLs than the other 
formulations. Moreover, by comparing the CD8+ T cell response stimulated by the 
MDDCs that were treated with the SL9-EAK16-II/R848 nanofibers to the one elicited by 
the MDDCs loaded with the mixture of SL9, EKA16-II and R848, it was implied that not 
only enhanced DCs maturation, but also the conjugating between the epitope and self-
assembling peptide played an essential role in the improvement of the CD8+ T cell 
response by SL9-EAK16-II/R848.  
It was notable that SL9-EAK16-II/R837 did not perform as efficiently as SL9-EAK16-
II/R848, while they exhibited a similar nanostructure (nanofibers) as well as a 
comparable efficiency in the maturation of MDDCs. This might be related to the fact that   
MDDCs from HIV-1 infected patients were severely impaired in their ability to stimulate 
T cells, though after stimulation, the expression of maturation markers on them was as 
up-regulated as on the ones from normal humans223,224. TLR7/8 agonist R848 but not 
TLR7 agonist R837 was reported with the capability to restore this dysfunction, since 
R848 could activate TLR7 and TLR8 synergistically on DCs to induce the production of 
IL-12, which played an important roll in T cell stimulation225. Consistent with these 
previous reports, our results suggested R848 could be preferentially used as an effective 
immune potentiator in the design for HIV-1 nanovaccine, such as SL9-EAK16-II/R848, 
in therapeutic vaccination.  	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4.4 Discussion	  
Peptide based vaccine that uses antigenic epitopes as the immunogen offers considerable 
advantages over the traditional ones generated from killed or attenuated microorganisms. 
However, the intrinsic immunogenicity of epitope is normally weak, which is mainly 
ascribed to the ease of proteolytic degradation and the lack of “danger signal. Thus, an 
efficient adjuvant should provide not only protection against degradation, but also 
activating innate immunity. Our previous results have demonstrated the self-assembling 
peptide EAK16-II can effectively shield the epitope from rapid degradation. However, 
the conjugating peptide itself failed to activate DCs, which provide a crucial link between 
the innate immunity and the acquired immune protection31. The activation of pattern-
recognition receptors (PRRs) on DCs can cause DCs up-regulating MHC and co-
stimulatory molecules, providing “signal 2” for the interactions between DCs and T 
cells127.   In the absence of this co-stimulatory signal, immune tolerance rather immunity 
is induced226.  Therefore, the incorporation of immune potentiators that can mimic the 
“danger signal”—pathogen-associated molecular pattern (PAMP) of microbial pathogens, 
is necessary for our self-assembling peptide based system to induce potent cellular 
response.  
TLRs, which have been well characterized as an important type of PRRs, can activate 
DCs and produce predominantly Th1 cells evoking cell-mediated immune response31. A 
number of TLR agonists have been developed to active cognate receptors, as adjuvants 
for vaccine design33. Up to date, only TLR 4 agonist monophosphoryl lipid A (MPLA) 
and TLR 7 agonist R837 are licensed for human use, with the later one only approved for 
topical administration. The combination of TLR agonists with antigen can be achieved 
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with various strategies, including directly mixing, linking with chemical bond, and co-
delivery within nanoparticles (NPs). However, compared with using protein as antigen, 
there are much less works for the co-delivery of peptide antigen and TLR agonist with 
NPs published. Torben and colleagues reported when T cell epitopes from Friend Virus 
(FV) were co-encapsulated with TLR 9 ligand CpG inside calcium phosphate NPs, the 
NP-based peptide vaccine induced potent T cell response and provided efficient 
protective immunity during acute and chronic virus infection227.  Besides, both liposomes 
and PLGA microparticles were also applied for the co-delivery of antigenic peptides and 
the agonist CpG, to enhance the antigen specific T cell response in vivo228,229. Either 
conjugation or surface absorption was adopted for the loading of CpG. For our EAK16-II 
based delivery system, it has been studied as an efficient vehicle to deliver/stabilize 
hydrophobic molecules, such as anticancer drugs230. Therefore, two hydrophobic 
imidazoquinoline derivatives, R837 and R848, which activate TLR7/8, were incorporated 
into our CD8+ T cell epitope loaded peptide SL9-EAK16-II.  
The self/co-assembly between amphiphilic SL9-EAK16-II and the hydrophobic agonist 
was investigated with fluorescence spectroscopy and ITC. As a much used “hydrophobic 
probe”, 1,8-ANS was considered to bind with hydrophobic surfaces and its fluorescence 
blued-shirted with enhanced intensity216. The ANS assay with SL9-EAK16-II suggests 
the self-assembled nanostructure from the conjugating peptide can provide a hydrophobic 
interior for the residence of hydrophobic molecules.  The intrinsic fluorescence intensity 
of the agonist (R837 or R848) also increased with the addition of SL9-EAK16-II, 
suggesting a more hydrophobic environment where the agonist resides. These implied the 
hydrophobic interaction played an important role in the co-assembly process. Moreover, 
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the maximum emission wavelength of the agonist was observed with blue shift when the 
agonist was mixed with SL9-EAK16-II. This might be due to that the π-conjugate of the 
quinolone ring extended by the substitute of amino group was weakened or impaired by 
the addition of the peptide molecules, resulting in the energy difference between the first 
singlet-spin excited state (S1) and singlet-ground state increasing (S0)231. The results from 
ITC further confirm the interactions involved in the self-/co-assembly. From our results, 
the SL9-EAK16-II/R837 (or R848) co-assembly was favored by both enthalpy and 
entropy. The entropy-driven binding is primarily correlated with hydrophobic 
interaction217, which was supported with the fluorescence assay. Additionally, the 
computer modeling combined with crystal structure analysis of TLR7/8, reveals that 
when R837 or R848 binds with its corresponding TLR, both the hydrophobic cores 
provided by the TLR’s Leucine-rich region and the hydrogen bonds formed between the 
agonist and the side chain of Aspartic acid (Asp), are important for the recognition and 
activation232,233. The Glutamic acids (E) in the sequence of SL9-EAK16-II could provide 
similar hydrogen bonding sites as Asp did. This hydrogen bonding can be highly 
associated with the negative enthalpy change. Thus, not only hydrophobic interaction, but 
also hydrogen bonding participates in the co-assembly process between SL9-EAK16-II 
and the agonist.  
Moreover, the SL9-EKA16-II/agonist co-assemblies maturated significantly more 
MDDCs, which subsequently stimulated more SL9 specific CTLs in-vitro, than the 
simple mixture of SL9 and agonist. Collectively speaking, with direct conjugating and 
co-assembly by non-covalent interaction, EAK16-II based platform successfully co-
deliver an antigenic peptide and a hydrophobic TLR agonist to DCs, which offers a 
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simple, yet efficient strategy to formulate a peptide based vaccine. However, as here the 
immunogenicity of this nanovaccine was only measured in-vitro, further assessment in 
vivo would be crucial for the application of the self-assembling peptide for vaccine 
design.  	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Chapter	  5 Enhanced	  HIV-­‐1	  specific	  primary	  CD8+	  T	  
cell	  response	  elicited	  by	  the	  co-­‐delivery	  of	  CD4+,	  CD8+	  
epitopes	  along	  with	  R848	  with	  self-­‐assembling	  peptide	  	  
Abstract 
Peptide based subunit vaccine can induce potent cellular response when the antigens are 
administrated in the presence of efficient adjuvants or delivery system. Our previous 
findings demonstrated EAK16-II based self-assembling peptide could effectively protect 
antigen epitope from degradation, and succeeded to incorporate both epitope and TLR 
agonist within the same nanostructure to stimulate more polyfunctional CD8+ T cells in 
vitro. Nevertheless, to prime long-termed and potent CD8+ T cell response in vivo is 
highly CD4+ T cell dependent. In the current chapter, not only CD8+ T cell epitope 
(SL9) and TLR agonist (R848), but also a CD4+ T cell epitope was formulated into the 
EAK16-II based delivery platform to obtain multifunctional nanoparticle based vaccine. 
Physicochemical characterizations revealed the morphology (nanofibers) and 
hydrodynamic size (~220nm) of the multifunctional nanoparticle, as well as the co-
assembling process involved in the formulation. Mice subcutaneously vaccinated with the 
multifunctional nanofibers generated significantly more SL9 specific CD8 + T cells, 
compared with either the mixture of two epitopes and R848 or R848 alone. Furthermore, 
The CD8+ T cell response generated upon nanofibers vaccination displayed central 
memory phenotype. The findings in this chapter further demonstrated the potential of the 
self-assembling peptide EAK16-II as the delivery platform for peptide based vaccines.  
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5.1 Introduction	  
As the vaccine developments orientate towards the less immunogenic “minimalist” 
components, such as DNA, protein, or peptides, the artificial formulations mimicking the 
killed or attenuated pathogenic microorganisms have been studied intensively. An 
optimal subunit vaccine should be considered with three components: (1) antigen, which 
provides the pathogen specific epitopes to regulate the targeting of the immune response 
(humral and/or cellular immunity), (2) immune potentiator that directly activates innate 
immune cells providing pro-inflammatory context for antigen recognition, (3) delivery 
system enhancing the targeted delivery of the antigen and the immune potentiator to 
innate immune cells, such as dendritic cells (DCs)9, which play a key role in bridging 
innate and adaptive immunity.  
Nanoparticles with the size smaller than 1000 nm have attracted increasing interest in 
formulating these subunit vaccines, owning to its flexibility in the selection of matrix 
materials, controllability over components, size, shape and surface properties44,93,227.  Our 
previous results suggested EAK16-II based self-assembled nanofibers, which 
incorporated an antigenic epitope and a TLR agonist within one particle efficiently 
enhanced the epitope specific cytotoxic T cell  (CTL) response as the form of DC based 
vaccine in-vitro. However, the ex vivo generation of DCs made the vaccine preparation 
complicated, and limited the stability and convenience of the vaccine. Thus, to determine 
whether the self-assembling peptide based nanofibers could be subcutaneously 
administrated in vivo, to elicit potent CTL response, would be critical for the application 
for the self-assembling peptide as a platform for the vaccine design. Though the existence 
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of TLR agonist can provide pro-inflammatory cytokines required for the full activation of 
antigen presenting cells, and bypass the need from CD4+ T cells to prime potent CTL 
response as proposed in some animal works234–236, recent studies have suggested the 
necessity of CD4+ T cell help in the generation of long-lived, functional memory CD8+ 
T cells that respond rapidly towards secondary exposure to pathogens127,237–239.  
Thus, in current study, to harness the self-assembling peptide formed nanofibers (the 
SL9-EAK16-II/R848 co-assemblies) with the capacity to stimulate CD4+ T cell response, 
we incorporated an additional T helper (Th) epitope by conjugating with EAK16-II, 
which further co-assembled with SL9-EAK16-II prior to the addition of R848.  The 
obtained multifunctional nanoparticle based vaccine was tested in HLA-A2 transgenic 
mice by the prime-boost strategy for the determination of T cell immunity. The results 
suggested EAK16-II based self-assembling platform successfully integrated the CTL, Th 
epitopes, and the TLR agonist (R848) within the nanofibers. The mice vaccinated with 
these nanofibers produced significantly more memory SL9 specific CD8+ T cells, 
compared with the ones with the mixture of epitopes and R848, or R848 alone.  
5.2 Materials	  and	  methods	  
5.2.1 Materials	  
All peptides in animal study were purchased from CanPeptide (Montreal, Canada), which 
were further treated with VariPure IPE column (Agilent, Canada) to remove remaining 
trifluoroacetic acid (TFA), followed with lyophilization in lab prior to use. HLA-A2 
transgenic mice were bred in the Division of Comparative Medicine at University of 
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Toronto. The experiment was conducted on female mice of 6-8 weeks old. All animal 
works were approved by University of Toronto, University Animal Care Committee. 
5.2.2 Methods	  
Circular Dichroism (CD) spectra Far-UV circular dichroism spectra of peptide samples 
were measured at room temperature using a Jasco J-815 CD spectrometer (Tokyo, Japan). 
150µL peptide solution was scanned in a 0.1cm quartz cell from 190 to 250nm. Solvent 
spectrum was used as the baseline for data collection.  
Morphology characterization with Atomic Force Microscopy (AFM) and 
Transmission Electron Microscopy (TEM) Atomic force microscopy was used to 
determine the nano-structures of peptide self-assemblies. 100µL sample solution was 
dropped on the surface of a freshly cleaved mica sheet for various times ranging from 
5mins to 30mins, depending on the concentration of solution. Then free peptide was 
removed by blotting, and washed with 300µL pure water. After an air-dry of a couple of 
hours, AFM imaging was taken at room temperature using the Peak Force tapping mold 
on a Dimension Icon AFM (Bruker, Santa Barbara, CA).  To confirm the structures 
acquired from AFM, TEM was also utilized. 10µL peptide solution was applied to a 400 
mesh Formvar coated copper grid for 3-5 minutes, followed by negative staining with 
10µL 2% uranyl acetate, blotted drying, and analysis on TEM (Philips CM10 TEM, 
operating at 60KeV). 
Particle size measured by dynamic light scattering (DLS) The hydrodynamic diameter 
of sample was measured using DLS on a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK) equipped with a 4mW He-Ne laser operating at 633nm. 50µL solution was 
added in low volume disposable polystyrene cuvette and the scattered light intensities 
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were collected at an angle of 173°. Three independent measurements were performed to 
generate the intensity based size distribution profile. 
Surface tension measurement Axisymmetric drop shape analysis-profile (ADSA-P) was 
used to measure the surface tension of peptide solutions prepared in pure Milli-Q water at 
various concentrations. The experimental setup for the measurement of dynamic surface 
tension was described previously240. The data was acquired every 30s, for the duration of 
5400s. The equilibrium surface tension was estimated by averaging 5 data points at the 
end of each dynamic surface tension profile and plotted versus concentration of peptide.  
Fluorescence spectroscopy A Photon Technology International spectrafluorometer 
(Type LS-100, London, Canada) with a pulsed xenon lamp as light sauce was utilized to 
measure the fluorescence spectra of R848 to study the interaction between peptide and 
agonist. Samples (70 µL) were transferred to a quartz cell (1cm × 1cm), which were 
exited at 248nm. The emission data was collected in the range of 300-450nm. Different 
volumes of SL9-EAK16-II/TL13-EAK16-II solution were added to the fixed agonist 
concentration at 15 µM to obtain peptide/agonist molar ratio from 0.5:1 to 6:1.  
Isothermal Titration Calorimetry (ITC) For all ITC experiments performed on Nano-
ITC (190µL, TA instruments, New Castle, DE) at 298K, Milli-Q water was carried out as 
described in previous chapter. Generally, the mixture of epitope-loaded self-assemling 
peptides or the mixture of epitopes with the total peptide concentration at 400µM was 
titrated into 20µM R848 solution. Blank titrations of peptides into pH 6.0water were 
performed to measure the heat of dilution of each peptide, which was subtracted from the 
integration data prior to curve fitting. Origin 8 software was used to fit the heat profiles, 
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assuming one-site binding. For each peptide solution, experiments were conducted three 
times.  
Cellular immune response CD4+ or CD8+ T cell epitope loaded self-assembling 
peptide was dissolved in sterile water at 0.4mM, which was then mixed at equal volume, 
and incubated at 4°C overnight. The mixture was further stirred in the presence of 0.1mM 
R848 overnight.  HLA-A2 transgenic mice were vaccinated subcutaneously at tail base 
twice with a 2-week interval between immunizations. For each injection, mice received 
500µL of samples or phosphate buffer saline (PBS) (for naïve control group). Two weeks 
after the second vaccination, spleens were taken from mice and splenocytes were 
prepared, which were then stained with PE-labelled SL9-dextramer (Immudex, 
Copenharge, Danmark) and anti-mouse CD3/CD8/CD62L/CD44 mAb (Biolegend, San 
Diego, CA).  Flow cytometry was run on a LSRII flow cytometer (BD Bioscience, San 
Jose, CA) and data were analyzed with FlowJo software (FlowJo, Ashland, OR).  
Statistical analysis Statistical analysis was performed by one-way ANOVA with 
Tukey’s test for comparison between groups. Group mean difference were considered 
statistically significant according to a p value < 0.05.  
5.3 Results	  
5.3.1 Preparation	  and	  characterizations	  of	  multifunctional	  nanofibers	  
based	  vaccine	  
The conjugating of IAb-restricted HBVc128 Th epitope (TPPAYRPPNAPIL, here 
referred to TL13) with EAK16-II was carried out as similarly as we did for the CD8+ T 
cell epitope SL9. The CD4+ T cell epitope-loaded conjugating peptide (named as TL13-
	   92	  
EAK16-II) is shown in Fig 5-1a.  Firstly, we investigated the secondary structures of the 
peptides with circular dichroism. SL9 was unstructured and the secondary structure of 
SL9-EAK16-II was dominated by α-helix, which were consistent with our previous 
results. For TL13 and its conjugating peptide TL13-EAK16-II, the mixed conformation 
of random coil and β-sheet was observed for the Th epitope, while TL13-EAK16-II 
adopted an α-helical structure, similarly with SL9-EAK16-II, as shown in Fig. 5-1b.   
	  
Figure 5-1 Schematic and sequences of TL13-EAK15-II, the molecular structures were stimulated with 
HyperChem, displaying carbon with black, nitrogen with cyan, oxygen with white, and secondary structure 
shown as blue ribbon (a); the conformational structures of the peptides were characterized by CD spectra.  
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Figure 5-2 The morphology of SL9-EAK16-II/TL13-EAK16-II co-assemblies was characterized with AFM 
(a) and TEM (b); schematic of the co-assembly between the two peptides (c); the intensity based 
hydrodynamic size of the co-assemblies was obtained from DLS (d). 
To formulate the self-assembling peptide based nano-vaccine, two epitope-loaded 
peptides were mixed at the molar ratio of 1:1 in advance, and incubated at room 
temperature over night, which was followed by the addition of R848 at the molar ratio of 
4:1 (peptide over agonist), and then stirring overnight. SL-EAK16-II/TL13-EAK16-II co-
assemblies were visualized dominantly as globular particles with the diameter of ~17nm, 
and small fraction of short fibrilar structures with the average length of ~74nm, from 
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AFM image (Fig.5-2a), which was further confirmed with TEM (Fig. 5-2b). The possible 
assembly mechanism was proposed as in Fig. 5-2c, relatively more hydrophobic epitope 
part of the peptides would aggregate in the core of the globular structure, with the 
EAK16-II moiety in the sequence forming the shell of the structure, driven by 
hydrophobic interactions, and hydrogen bonding. The hydrodynamic size of the peptides 
co-assembles was measured by DLS (Fig. 5-2d), with a main population at  ~21nm, 
which was comparable with the size of the globular particles analyzed from the AFM 
image (Fig. 5-2a)  
 By contrast, with the addition of R848, the morphology of the co-assemblies of SL9-
EAK16-II/TK13-EAK16-II/R848 altered to cross-linked nanofibers characterized with 
AFM (Fig. 5-3a) and TEM (Fig.5-3b), and the main size of the co-assemblies shifted to 
~220nm, as shown in Fig. 5-3d. Our previous results suggested when SL9-EAK16-
II/R848 co-assembled into nanofibers, the hydrophobic molecule R848 was encapsulated 
within the interior environment of the peptide-formed aggregates. A similar co-assembly 
mechanism was proposed for SL9-EAK16-II/TL13-EAK16-II/R848 (Fig.5-3c), since 
SL9-EAK16-II and TL13-EAK16-II exhibited the same helical structure. Furthermore, 
previous reports suggest that the particle size of antigen smaller than 200nm can directly 
enter the lymphatic system, and efficiently internalized by plasmacytoid DCs to IFN-α 
that can efficiently facilitate the direct priming of CTLs241–243.  
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Figure 5-3 The conjugating peptides mixture was further added with R848 at the molar ratio of 4:1 (peptide 
to agonist), the morphology of the tripartite system was characterized with AFM (a) and TEM (b); 
schematic of the mechanism for the forming of nanofibers, the arrows represent the growing orientations of 
the fibers(c); size distribution of the tripartite nanofibers (d).   
To investigate the interaction between the two epitope-loaded peptides, surface tension 
method was applied, which was widely used to study the interactions involved in the 
mixing of binary surfactants system244. The dynamic surface tensions at different 
concentrations were acquired for SL9-EAK16-II (Fig.5-4a), TL13-EAK16-II (Fig.5-4b) 
and the mixture of them at the molar ratio of 1:1 (Fig.5-4c), from which the equilibrium 
surface tension for each concentration was obtained for the relative peptide, as 
summarized in Fig.5-5.  
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Figure 5-4 Dynamic surface tension of SL9-EAK16-II (a), TL13-EAK16-II (b), and 1:1 mixture of the two 
peptides (c) at different concentrations.  
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For these peptide solutions, they exhibited a similar trend, as at the low concentrations, 
the equilibrium surface tension decreased with the peptide concentration increasing, 
while the concentration increased to certain value, the surface tension approached a 
plateau, from which the critical aggregation concentration (CAC) could be estimated. The 
CAC for SL9-EAK16-II was ~7µM, which was consistent with our previous data, while 
for TL13-EAK16-II it was ~64µM.  
	  
Figure 5-5 The equilibrium surface tension profiles for SL9-EAK16-II, TL13-EAK16-II and the mixture at 
the molar ratio of 1:1 were obtained and plotted as the function of peptide concentration; the dashed line 
was predicted by real solution theory for the ideal mixture of the two peptides.  
By contrast, when the two peptides mixed, the CAC was estimated at ~9µM. The mixing 
of a binary system can be described with the regular solution theory as Eq.1.  
 
1!!"#! = !!!! ∗ !!! + !!!! ∗ !!! !! （1）  
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Where 𝐶!! , 𝐶!! , or 𝐶!"#!  is the concentration of species 1, 2 or the mixture that 
individually produces the surface tension of certain value π, α1 or α2 is the fraction of 
each component in the bulk solution, and f1 or f2 is the activity coefficient. When the 
mixing is ideal, namely there is no interaction between the two species, the activity 
coefficient equals to 1. Thus, the surface tension profile for an ideal mixing could be 
predicted from Eq.1.  For a given value (π), the concentration of SL9-EAK16-II or TL13-
EAK16-II that produced such a surface tension could be read from the experimental 
equilibrium surface tension curve (blue or red straight line in Fig. 5-5). Then the 
concentration of the ideal mixture acquired to produce the same surface tension was 
calculated from Eq.1. From a series of π values and the corresponding concentrations, the 
predicted equilibrium surface tension profile for the ideal mixture was obtained, as shown 
with dashed line in Fig.5-5. Obviously, the mixture of the two peptides in real case did 
not follow the pattern of the ideal mixture, which suggested there could be interactions 
between them. The interaction parameter can be estimated from Eq.2.  
 
Where β is the interaction parameter, x1, or x2 is the fraction of each component in the 
micelle, with other variables representing the same meanings as in Eq.1. At the CAC of 
the mixture of SL9-EAK16-II and TL13-EAK16-II (mixed at 1:1 molar ratio), the 
iterative solution of Eq.2 was -2.38 for interaction parameter, and 0.76 for the fraction of 
SL9-EAK16-II in the micelles formed by the two peptides. By contrast, in the case of 
ideal mixing, the interaction parameter equaled to 0, and the predicted composition of 
micelle was 0.93 for SL9-EAK16-II. From the comparison with the ideal mixing 
predicted from the regular solution theory, the interaction between the two peptides were 
! = 1!!! ∗ ln !! ∗ !!"#!!! ∗ !!! = 1!!! ∗ ln!(!! ∗ !!"#!!! ∗ !!! )! （2）  
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illustrated, which suggested the presence of the two peptide within the same 
nanostructure. And this co-existence of the two epitopes within the nanofibers would 
facilitate the co-recognition, since it was suggested that CD4+ and CD8+ T cell must 
recognized the antigens from the same antigen presenting cells for the generation of 
functional memory CD8+ T cells245. 
  
Figure 5-6 The interaction between peptides mixture and R848 was studied with fluorescence spectra.The 
fluorescence spectra of R848 in the mixture solution of SL9-EAK16-II and TL13-EAK16-II at different 
peptide concentrations (Top), and the intensity ratio I326/I356 was determined and plotted versus molar ratio 
(bottom).  	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Then we utilized fluorescence spectra to investigate the co-assembly process between the 
peptides and the TLR agonist R848, as shown in Fig. 5-6. Consistent with previous 
results, when R848 was mixed with the peptide solutions, λmax blue shifted to ~341nm, 
and the intensity of emission peak at 326nm also increased with the peptide concentration 
increasing, while the intensity at 356nm decreased, indicating the interactions such as 
hydrogen bonding and hydrophobic interaction participated in the co-assembly between 
R848 and the peptides. The molar ratio for saturation binding was approximately at 3:1 
(peptide to R848), as illustrated in Fig.5-6 (bottom).  
	  
Figure 5-7 Isothermal titration profiles for peptides solutions injected into R848. The mixture of 
conjugating peptides into R848 (a); the mixture of epitopes into R848 (b) 
The calorimetric titration profiles for the mixture of epitope conjugating peptides or the 
mixture of epitopes into R848 were shown in Fig. 5-7. And the thermodynamic 
parameters for the two bindings were summarized in Table 5-1. Similar to the injection of 
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SL9-EAK16-II into R848 as discussed in Chapter 4, the binding between SL9-EAK16-
II/TL13-EAK16-II and R848 was exothermic process, which was favored by both 
enthalpy and entropy.  
Table 5-1 Thermodynamic parameters (mean ± SD, n=3) obtained with ITC 
 
SL9-EAK16-II + 
TL13-EAK16-II 
SL9 + 
TL13 
ΔH (kJ mole-1) -23.73±0.93 40.87±4.19 
ΔS (J mole-1 K-1）  38.06±4.02 203.94±3.76 
TΔS (kJ mole-1) 11.34±1.20 60.77±1.12 
Kd (µM) 0.72±0.04 343.27±5.09 
N 3.66±0.40 0.71±0.34 	  
By contrast, an endothermic binding driven by entropy between the mixture of epitopes 
and R848 was observed, which was different from the result for SL9/R848 as shown in 
Chapter 4. This might be resulted from the different self-assembling behaviors of TL13 
and SL9. As shown in the CD spectra, TL3 exhibited both random coil and β-sheet, while 
SL9 was unstructured random coil. From the AFM images (data not shown), the β-sheet 
structural TL13 could assemble to nanofibers by itself, which possibility co-assembled 
with R848 in the mixture. However, the obtained binding affinity (Kd =343.27μM) 
between the epitopes and R848 was relatively weak. The concentration of R848 in the 
mixture of SL9/TL13/R848 that was used for in vivo study was 100µM, lower than the 
dissociation constant Kd. This implied when the mixture was injected into mice, the weak 
binding between the epitopes and R848 could be neglected.  
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5.3.2 Multifunctional	  nanofibers	  primed	  significantly	  more	  potent	  CTL	  
response	  that	  displayed	  central	  memory	  phenotype.	  
	  
Figure 5-8 HLA-A2 transgenic mice were subcutaneously vaccinated with SL9/TL13/R848, R848 alone, 
SL9-EAK16-II/TL13-EAK16-II/R848, and PBS as naive control group, following the schedule illustrated 
in (a); at day 28, the mice were sacrificed, and the lymphocytes were then collected from spleens. 
Dextramer flow cytometry was applied to measure the number of SL9 specific CD8+ T cells. A 
representative flow cytometry profile from one mice were shown, in which the numbers presented the 
percentage of SL9-specific CD8+ T cells in the total CD8+ T cells (b). The frequencies of SL9 specific 
CD8+ T cells from mice vaccinated with different antigen formulations (c). 8 mice per group, * P<0.05, ** 
P<0.01.  The central memory antigen specific CD8+ T cells were stained with CD62L+CD44+ from flow 
cytometry (d), in which the number presented the percentage of memory CTLs in the total CD8+ T cells.  
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Then we evaluated the cellular immunity of the different antigen formulations in vivo. 
HLA-A2 transgenic mice were injected subcutaneously with SL9-EAK16-II/TL13-
EAK16-II/R848, SL9/TL13/R848, or R848, with PBS as naïve control, following the 
vaccination schedule as shown in Fig. 5-8a. At day 28, the splenocytes were collected 
from mice, and stained with fluorophore labeled SL9-dextramer, anti-mouse CD3, CD8, 
CD62L and CD44 mAbs, for the analysis with flow cytometry. The frequencies of SL9-
Dextramer positive CD8+ T cells were showed in Fig. 5-8b and 5-8c. It was observed 
that more SL9 specific CD8+ T cells were generated in the mice vaccinated with the 
nanofibers, compared to in the ones with the mixture of epitopes and R848 (p<0.01), or 
R848 alone (p<0.05). An ideal prophylactic vaccine for inducing cellular response should 
generate memory CD8+ T cells, which respond rapidly to the secondary infection246. 
Therefore, we further analyzed the phenotypes of the SL9 specific CTLs according to the 
expression of the surface markers CD62Lhigh and CD44high, which were the characteristic 
of memory CD8+ T cells247,248.  As shown in Fig.5-8d with the red frame that represented 
the CD62L/CD44 double positive CTLs, 89.5% of SL9 specific CD8+ T cells displayed a 
central memory phenotype. These results demonstrated not only an enhanced magnitude, 
but also a higher quality of T cell response was induced by the nanofibers-based vaccine. 
By priming the memory CD8+ T cells against HIV-1 antigen SL9, in theory the memory 
CTLs could respond immediately after the virus infection.  
5.4 Discussion 
In this chapter, we incorporated a CD4 epitope-bearing EAK16-II into SL9-EAK16-
II/R848 nanofibers to formulate a nanovaccine. The surface tension studies revealed the 
interaction between SL9-EAK16-II and TL13-EAK16-II, and the further co-assembly 
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between the conjugating peptides and R848 was studied by fluorescence spectra and 
calorimetric titration. These results demonstrated the integration of the CD4, CD8 
epitopes and the TLR 7/8 agonist R848 into the same nanostructure with the presence of 
the self-assembling peptide EAK16-II. The nanovaccine stimulated significantly more 
SL9 specific central memory CTLs in HLA-A2 transgenic mice, compared with either the 
mixture of epitopes and TLR agonist, or the TLR agonist alone.  
When the CD4+ or CD8+ T cell epitope was conjugated with EAK16-II, a α-helical 
secondary structure was obtained. Though the conformational structure is not required by 
T cell epitopes biding with MHC molecules for the presentation to T cells, it is crucial to 
generate B cell epitopes with conformations that resemble the native protein for the 
induction of potent humoral response24. However, it was very challenge for synthetic 
epitopes to fold into helical structure by themselves, or even delivered by other NPs 
based platforms, such as liposomes, or polymeric NPs. Our EAK16-II peptide offers a 
promising strategy to promote the conformational structure of epitope, especially for non-
linear B cell epitope. Moreover, though our understanding of how CD4+ T cells and 
CD8+ T cells interact has been improved remarkably, the role of CD4+ T cell help for the 
primary CTL response remains an open question127. Olivier and colleagues229 reported 
that liposome-encapsulated CD8+ T cell epitopes did not require the help from CD4+ T 
cells or immune potentiators to prime CTLs in HLA-A2.1 mouse model.  However, more 
recent studies have shown that the generated memory CTLs with the absence of T cell 
help are defective in the induction recall response following secondary challenge236,238,239. 
Thus, it is very important to investigate the importance of CD4+ T cell epitope in our 
self-assembling peptide based nanovaccine in future.  
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Our most recent in-vivo study suggested that when the antigen either mixture of epitopes 
and R848 or the nanovaccine was injected, most of the fluorophore labeled antigen was 
taken up by DCs, which are considered as the most crucial APCs for the induction of T 
cell response. Moreover, the fluorophore labeled nanovaccine persisted a longer duration 
inside DCs than the mixture of epitopes and R848, which was consistent with our in-vitro 
study discussed in Chapter3. As we did not incorporate any DC targeting ligand, why the 
nanovaccine was primarily found in DCs remains unclear for us. The physical attributes 
of NPs, such as size, shape, surface charge, and hydrophobicity can strongly influence the 
adjuvant properties242,249.  A number of research findings have been reported and 
attempted to establish a correlation between the particle properties and the produced 
immune response, whereby, these reports are conflicting and debated131,132,241,242,250–255.  
For the purpose of targeting lymphoid DCs, NPs of 20-200nm, are preferable to larger 
particles, since the smaller particles can directly reach the lymph nodes242. The 
hydrodynamic size of our nanovaccine was measured as ~220nm, which is slightly larger 
than the top limit of the criterion. Thus, our nanovaccine could be captured and carried 
into initial lymph node by peripheral DCs in the injection site.    
Molecular definition is becoming more favored for the vaccine design. To induce precise 
immune response with simple mechanism, NPs have been intensively studied for the 
delivery of antigenic peptide, among which Liposomes and polymeric NPs are the most 
used materials. We did not conduct a head-to-head comparison against these materials in 
our animal work, so there is no quantitative readout to compare the efficiency of our self-
assembling peptide with them. Over liposome or polymeric NPs, the self-assembling 
peptide can offer a number of unique characteristics. First, the loading of antigen to self-
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assembling domain is easily achieved by peptide synthesis, with higher antigen loading 
capacity. In contrast, liposomes and polymeric NPs normally deliver antigen with 
encapsulation, with which the loading capacity is much lower, and the integrity of the 
antigen might be impaired, since organic reagents, extrusion, or ultra-sonication were 
applied. Also, the self-assembling peptide can be applied to control the secondary 
structure of conformational B cell epitope.  Moreover, highly repetitive display of 
antigenic peptides on nanoscale particles can be directly obtained from the self-
assembling of peptide molecules. However, there are also some drawbacks for the self-
assembling peptide based system when applied for antigen delivery. Compared with 
liposome or polymeric NPs, which can provide a gradual release of antigen up to 8-10 
weeks, the self-assembling peptides are easily degraded, which would be the biggest 
obstacle for the application in vaccine delivery. Moreover, due to the nature of self-
assembling peptide, when it is used with the presence of potent immune potentiator, 
possible immune response against its sequence might be primed, which is necessary to 
confirm in future.   
Generally, self-assembling peptide provides a simple, chemically defined strategy for 
enhancing cellular response to peptide epitopes.  	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Chapter 6 Original Contributions and 
Recommendations 
6.1 Original contributions to research 
This thesis presented the application of the self-assembling peptide EAK16-II as a 
delivery platform in the formulation of HIV-1 peptide-based vaccine. With direct 
conjugation and non-covalent encapsulation, the HIV-1 highly conserved T cell epitopes 
and the TLR agonists were integrated within the nanostructure, which was evaluated for 
immunogenicity either in the form of DC-based vaccine in vitro, or a prophylactic 
vaccine in vivo. Three progressive parts were involved: (1) the synthesis and 
characterizations of HIV-1 CD8+ T cell epitope-bearing peptide, which was 
demonstrated to form nanofibers with improved extra/intra-cellular stability and 
enhanced cross-presentation efficiency by DCs; (2) the co-delivery of the antigenic 
epitope and the TLR agonists within the same nanoparticle that further augmented the DC 
maturation and consequently enhanced CTL response in vitro; (3) the formulation of a 
peptide-based vaccine by integrating the epitopes and the TLR agonist with the presence 
of the self-assembling peptide to induce potent HIV-1 specific CTL response in vivo. The 
original contributions to research are summarized as following. 
Self-assembling peptide enhanced the cross-presentation efficiency of the epitope. 
The HIV-1 CD8+ T cell epitope SL9 was conjugated with the self-assembling peptide 
EAK16-II. Though a transition of the secondary structure from β-sheet for EAK16-II to 
α-helical structure for the epitope-bearing peptide occurred, SL9-EAK16-II still 
spontaneously aggregated to short nanofibers in PBS with the average hydrodynamic size 
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of ~103nm.  The stability studies in serum or oligopeptidase demonstrated the 
conjugating peptide was more persistent than epitope alone, proving our hypothesis that 
nanostructure would prevent the epitope from degradation by proteases or peptidases. Ex 
vivo generated DCs pulsed with the nanofibers stimulated more poly-functional CTLs 
when co-cultured with PMBCs from HIV-1 infected individuals. Our data suggested this 
enhancement was beneficial from not only the sustained antigen level within DCs, but 
also the more efficient endosomal escape. However,	  the epitope-loaded nanofibers could 
not maturate DCs by itself, namely requiring the addition of immune potentiator to avoid 
causing tolerance.  
The co-delivery of epitope and TLR agonist with the self-assembling peptide 
promoted the antigenicity of the epitope. The TLR agonist (R837 or R848) that could 
target and activate innate immunity to provide pro-inflammatory environment, was 
incorporated into the epitope-loaded nanofibers, by non-covalent interaction. It was 
suggested from calorimetric titration and fluorescence spectra that the co-assembly 
between the self-assembling peptide and the TLR 7/8 agonist was mainly driven by 
hydrogen bonding as well as hydrophobic interaction, and the ideal molar ratio for 
peptide to carry TLR agonist was 4:1. AFM and TME confirmed the morphology of the 
co-assembly as interweaved nanofibers, with increased hydrodynamic size, which were 
quickly internalized to endosomal compartments by DCs. The increased expression of 
surface maker CD83 on DCs implied the addition of the TLR agonist enhanced the 
stimulation of these nanofibers towards DCs. Consequently, relative to the DCs loaded 
with the epitope or the mixture of epitope and TLR agonist, the ones pulsed with the 
nanofibers simulated more SL9-specific poly-functional CTLs in vitro. Notably, R848 
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was suggested as a preferential TLR7/8 agonist when designing the therapeutic HIV-1 
vaccine.  
Integrated formulation of a peptide-based HIV-1 vaccine with the self-assembling 
peptide as the delivery platform: To generate long lasting memory antigen specific 
CTLs, the help from CD4+ T cell is necessary. Thus, we conjugated a CD4 epitope with 
EAK16-II, which co-assembled with the previously described CD8 epitope-bearing 
EAK16-II. The morphology of the co-assemblies was characterized as globular 
nanoparticles. The integrated formulation of the peptide-based vaccine was obtained by 
further assembling between the two epitope-bearing peptides with the TLR7/8 agonist 
R848. Physicochemical characterizations revealed the formulation as cross-linked 
nanofibers with an average hydrodynamic size of ~220nm. Then we examined the 
immunogenicity of these nanofibers in the transgenic mice by subcutaneous vaccination. 
Remarkably, the mice treated by the nanofibers based formation produced more SL9 
specific memory CD8+ T cells, than either the mixture of epitopes and R848, or R848 
alone. This strongly supported the potential of self-assembling peptide as matrix to 
formulate efficient HIV-1 peptide vaccine with low cost and ease of manufacturing.  
6.2 Recommendations 
This project is still in progress, for which currently great efforts are focusing on the in-
vivo tracking of peptide, as well as measuring functionality of the in-vivo generated 
antigen specific CTLs.  Additionally, since some important control groups, including the 
antigen without R848, the antigen without CD4+ T cell epitope, and epitopes adjuvanted 
with IFA or CFA as positive control, were missing in the previous in vivo study, more 
animal work will be carried out in future. Furthermore, the enhancement of T cell 
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response provided by the current formulation of nanovaccine is not sufficiently potent to 
provide protection against infection, thereby, some recommendations are proposed for the 
formulation optimization, as discussed in the following.  
Firstly, the more CTL epitopes replacing SL9 should be tested in the transgenic mice to 
determine the enhancement by utilizing the self-assembling peptide is applicable to a 
broad range of epitopes, rather than any specific epitope. Moreover, since even in the 
“highly conserved” epitopes, residual variability still exists, the coverage of these 
immunogenic epitopes is not optimally sufficient. Inspired from the “mosaic” approach in 
engineering immunogen, a better CTL epitope can be artificially constructed to comprise 
more conserved epitopes in one sequence8. This strategy can contribute to generate a 
more efficient vaccine with a wider coverage. Alternatively, to avoid the potential risk of 
using such artificial epitope, we also can include more CTL epitopes in the vaccine 
formulation, rather than only one as we did in Chapter 5. Therefore, the self-assembling 
peptide might display the multiple CTL epitopes in the same nanoparticles, via co-
assembly process. Compared with the means with dendrimer, which was more 
complicated in synthesis and more difficult in purification256, this strategy exhibits 
obvious advantages in producing and manufacturing.  
Furthermore, as suggested by our results and previous reports, the cross-presentation 
efficiency is critical for the immunogenicity of an antigen, especially for the exogenously 
administrated peptides. Two possible strategies can be considered in the future work. The 
first one is to further enhance the endosomal escape efficiency of the system by 
incorporating cell-penetrating peptides such as TAT, or a moiety with “proton sponge” 
effect. The other is that we can utilize various linking spacers between the epitope and the 
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self-assembling peptide, such as proteasome preferentially cleaving sequence257, or 
replacing peptide bond with disulfide bond, which was suggested as an better choice for 
CTL response130,258.  
Last but not least, because of the central role of the dendritic cells in primary immune 
response, targeted delivery of the antigens to DCs is critically important for the design of 
an efficient vaccine. Despite the passively targeting strategies using nanosized or 
particulate vaccine carries, the most efficient approach is the actively targeting via the 
receptor-ligand interaction, such as mannose receptor, Fc receptor, and DC-SIGN (DC-
Specific Intracellular adhesion molecule-3 Gabbing Non-integrin) receptor259. Therefore, 
we can incorporate one of these targeting ligands with the self-assembling peptide, to 
enhance targeting efficiency towards DCs.  
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Appendix 
 
Method: 
Liposome leakage assay Calcein-loaded liposome was prepared by POPC/POPG (3:1) 
as described. In a quartz cuvette, 5µL POPC/POPG liposome was mixed with 595µL 
HEPES buffer (10mM, pH7.0), in which 10µL peptide solution was added. The kinetic 
fluorescence was monitored every 12s for 38mins before Triton X100 (10µL, 5%) was 
added to fully rupture the liposome and the fluorescence was read again.  
 
Results: 
 
 	  Figure	  6-­‐1	  MS	  spectrum	  of	  SL9.	  The	  theoretical	  MW=980.13	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  Figure	  6-­‐2	  MS	  spectrum	  of	  EAK16-­‐II.	  The	  theoretical	  MW=1655.85	  	  
	  Figure	  6-­‐3	  MS	  spectrum	  of	  SL9-­‐EAK16-­‐II.	  The	  theoretical	  MW=2866.18	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  Figure	  6-­‐4	  Kinetics	  of	  fluorescence	  increase	  indicated	  liposome	  rupture	  after	  mixing	  peptide	  solution	  with	  calcein-­‐loaded	  POPC/POPG	  liposome.	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